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Diabetes is a disease where the glucose level in the blood is high, due to either insulin resistance, 
impaired insulin sensitivity or no insulin production. The high glucose level causes several 
complications, one of them being an impaired wound healing process, which might lead to chronic 
wounds, ulcers. Several factors play a role in the development of ulcers, and recent research 
indicates that microRNA might play a significant role in skin development and wound healing. The 
purpose of this project is to identify, which microRNAs are increased or decreased in wound 
healing among diabetic mice and which processes they effect in the wound healing process. This 
project was based on a literature review and an experiment. Skin samples from diabetic and non-
diabetic mice were used in the experiment. The experiment was divided into three steps. First 
homogenization was used to release the RNA from the mice skin samples. Then RNA purification 
was performed to purify and isolate the RNA from the samples. Afterwards microarray was used to 
synthesize complementary DNA from a RNA template and detect the Ct values of each microRNA 
in the skin samples of the mice. Ten microRNAs were selected, on the basis of the results of the 
experiment, for further analysis in regards to wound healing. Furthermore six microRNAs were 
selected on the basis of present studies, which showed these microRNAs’ influence on wound 
healing. It was concluded that miR-126-3p, miR-133a, miR-191, miR-193b, miR-320, miR-342-3p, 
miR-574-3p and miR-150 possibly can influence the impaired wound healing among diabetic mice. 
The same was concluded for miR-210, miR-203, miR-205 and miR-92a. miR-155 and miR-200b 
however appeared to stimulate wound healing among diabetic mice.  
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This report is drawn up by 2
nd
 semester students of the Bachelor of Science on Roskilde University. 
The 2
nd
 semester theme is the interaction between theory, model, experiment and simulation in 
natural science. This project deals with microRNAs’ role in wound healing among diabetic mice. 
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Diabetes is a disease characterized by high glucose concentration in the blood. The high level of 
glucose in the blood can be caused by absence of insulin or a reduced amount of insulin because of 
β-cell destruction. A high level of glucose in the blood can also be caused by insulin resistance 
(DeFronzo et al., 2005; Reece et al., 2011). The disease diabetes can have a number of symptoms, 
one of them being a reduced function of the nerve system, causing reduced sensibility. Thus, 
diabetic patients can be less sensitive to wound formation (Apelqvist, 2013). In addition to reduced 
sensitivity they also have an impaired wound healing process. Wounds of diabetic patients are often 
not discovered; therefore they can potentially develop into chronic wounds, also known as ulcers 
(Apelqvist, 2013). The impaired wound healing can lead to the development of ulcers (reviewed by 
Lima et al., 2012; reviewed by Pastar et al., 2012). In some cases ulcers can lead to amputation 
(McClelland and Kantharidis, 2014). In 1993 microRNA (miRNA) was discovered (Reece et al., 
2011) and present research suggest that miRNAs are important to skin development and wound 
healing (reviewed by Banerjee et al., 2011). An up- or down-regulation of miRNAs in diabetic 
versus non-diabetic patients has also been observed (reviewed by Pastar et al., 2012). If the relevant 
miRNAs can be examined and determined, there might be a potential treatment for diabetic patients 
with ulcers (reviewed by Banerjee et al., 2010; reviewed by Pastar et al., 2012). This project will 
attempt to identify some of the relevant miRNAs through an experiment. These miRNAs will be 
explored by comparing and analyzing the ratio between the relative expression of miRNAs in skin 
samples from diabetic and non-diabetic mice. For a better understanding of miRNAs’ role in wound 
healing, this project will also describe the different processes in wound healing. The problem of 
PREFACE 
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interest is in hopes of discovering the relevant miRNAs in wound healing among diabetic mice. If a 
treatment for ulcers among diabetic patients can be developed through research, the amount of 
widespread diabetic ulcers may be reduced. Society and the healthcare system will therefore benefit 
financially and resource wise through this field of research. 
 
1.1 PROBLEM OF INTEREST  
Which miRNAs are increased or decreased, and what are they targeting, in regards to wound 
healing among diabetic mice, and which processes are involved in wound healing?  
 
1.2 TARGET GROUP 
The target group is people with an understanding of natural science, especially molecular biology 
corresponding to students on 2
nd
 semester of the natural science bachelor. 
It will be an advantage to have studied the courses cell biology and biological chemistry.   
 
1.3 RELATION TO THE SEMESTER THEME 
The 2
nd
 semester theme is the interaction between theory, model, experiment and simulation in 
natural science. It is the interaction between the theory and the experiment that will answer the 
problem of interest of this project. The theory will help answering the problem of interest by 
describing the wound healing processes and by discussing some miRNAs, which were selected on 
the basis of the experiment executed in this report. The experiment showed which miRNAs were 
increased or decreased in diabetic mice compared to non-diabetic mice.   
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2.1 DIABETES 
Diabetes mellitus is characterized by high blood glucose levels, caused by different factors 
depending on the type of diabetes (DeFronzo et al., 2005; Reece et al., 2011). Only type 1 and type 
2 diabetes will be described. A high level of glucose can be caused by insulin absence, a reduced 
amount of insulin or insulin resistance in cells or a combination of these (DeFronzo et al., 2005). 
The production of the hormone insulin takes place in the pancreas by β-cells. Among non-diabetic 
patients the release of insulin is regulated by the glucose level in the blood. When insulin binds to 
an insulin receptor on the plasma membrane of the target cell, a cascade of reactions is initiated, 
resulting in transportation of the glucose transport protein 4 (GLUT4) to the plasma membrane. The 
cascade reaction will not be further described in this report. When GLUT4 is in the plasma 
membrane, the cell assimilates glucose, until GLUT4 leave the plasma membrane, when the insulin 
receptor is no longer activated by insulin (Fig. 2.1) (DeFronzo et al., 2005).   
 
 
Fig. 2.1 An insulin receptor is activated by insulin, which starts a signal transduction that results in GLUT4 
in the plasma membrane. Thereafter cell exterior glucose diffuse through the GLUT4 into the cell (modified 
from Beta Cell Biology Consortium).  
The two main types of diabetes are type 1 and type 2. In both types there is no or very little glucose 
uptake in cells, therefore the metabolic need is not maintained and the cell needs other energy 
sources (Reece et al., 2011).  
2. THEORY  
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In type 1 diabetes, the β-cells are destroyed by cytotoxic T-cells (Reece et al., 2011). β-cells 
destruction leads to no or little production of insulin, therefore the target cells cannot assimilate 
glucose (DeFronzo et al., 2005; Reece et al., 2011). 
Type 2 diabetes is caused by insulin resistance or lack of insulin. The insulin cannot bind to the 
insulin receptor or the cascade of reactions does not proceed correct. Therefore the GLUT4 protein 
will not move to the plasma membrane, which results in no or little glucose uptake to cells 
(DeFronzo et al., 2005; Reece et al., 2011).  
 
2.2 WOUND HEALING 
Among diabetic patients, the wound healing process can be impaired (Apelqvist, 2013; Paster et al., 
2012. The actual wound healing is divided into four overlapping phases; the hemostatic phase, the 
inflammatory phase, the proliferative phase and the remodeling phase, in which a lot of different 
cells and proteins are involved (Fig. 2.2) (reviewed by Li et al., 2007). To understand the critical 
extent of the wound healing process being impaired among diabetic patients, the following sections 
will be described in this chapter; structure of the skin, the hemostatic phase, the inflammatory phase 
and the proliferative phase, which is divided into reepithelialization, fibroplasia and angiogenesis. 
At last the remodeling phase is described.  
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Fig. 2.2 A presentation of all the central cells in each phase and a time scale of a normal wound healing. The 
first two phases are the hemostasis and the inflammation, which starts within a few hours of injury. Then 
there is the proliferative phase, which is overlapping with both the inflammatory phase and the remodeling 
phase, which is contemporary with the hemostatic, the inflammatory and the proliferative phase (modified 
from reviewed by Li et al., 2007). 
 
2.2.1 STRUCTURE OF THE SKIN 
The most important function of the skin is to be a protective barrier that shields the body from 
physical and chemical damage from the environment. Furthermore, the macrophages located in the 
skin actively fight the infection (Voldum, 2000; Goodenough & McGuire, 2012). 
The skin consists of three layers: the epidermis is the outermost layer, the dermis is located between 
the epidermis and the innermost layer, called the hypodermis (Fig. 2.3) (Voldum, 2000). 
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Fig. 2.3 A structure of the human skin. The deepest layer is the hypodermis, above this layer is the dermis 
and on the top is the epidermis. In the epidermis is an area of rapidly dividing cells, called epithelial cells 
(modified from Goodenough & McGuire, 2012). 
 
The epidermis contains several layers of epithelial cells, which is rapidly dividing ( Voldum, 2000; 
Goodenough & McGuire, 2012). These newly made epithelial cells pushes the older cells toward 
the surface, where they die, because they cannot get nutrition from the dermis. This causes the 
keratin proteins, inside the cells, to replace the cytoplasmic contents within the cell and thereby 
creating the outermost layer made of keratin proteins (Voldum, 2000; Goodenough & McGuire, 
2012).  
The dermis is a thicker layer than the epidermis and consists mostly of connective tissue including 
collagen and elastic fiber. Furthermore, this layer contains nerve endings and blood vessels. The 
blood vessels deliver nutrition to the lower layer of the epidermis (Voldum, 2000).  
The deepest layer, the hypodermis, consists of loose connective tissue and fat storage (Voldum, 
2000). It functions as an anchor for the dermis and the tissues underneath (Goodenough & 
McGuire, 2012). 
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2.2.2 THE HEMOSTATIC PHASE 
When a wound occurs, the epidermis and the dermis of the skin have been damaged, which causes 
an activation of the hemostatic phase. The main function of this phase is to stop the bleeding (Fig. 
2.4). The establishment of a blood clot stops the bleeding (reviewed by Haertel et al., 2014). 
 
 
 
Fig. 2.4 Wound healing during the hemostatic phase. The bleeding stops by formation of a blood clot, which 
consists of fibrin, collagen, neutrophils and platelets  (modified from Gurtner et al., 2008).  
 
First, the blood vessels in the wounded tissue contract to minimize the amount of blood loss 
(reviewed by Velnar et al., 2009). The blood contains platelets that begin an interaction with the 
collagen molecules, causing the platelets to release clotting factors (Nelson & Cox, 2013). Different 
reactions are activated by the clotting factors and this leads to the formation of the enzyme thrombin 
(Reece et al., 2011). Thrombin is important for the formation of the blood clot. The enzyme cleaves 
fibrinogen causing fibrin to be established. Then fibrins gather in a framework of threads which 
leads to an establishment of the clot (Reece et al., 2011), consisting of fibrin, collagen molecules, 
neutrophils and platelets (reviewed by Haertel et al., 2014). 
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2.2.3 THE INFLAMMATORY PHASE 
The second phase of wound healing is the inflammatory phase. In this phase, different leukocytes 
begin infiltrating the site of the wound. These leukocytes are important for the suppression of 
pathogens that may enter the wound, and furthermore they are important for the degradation and the 
formation of tissue (reviewed by Eming et al., 2007). 
The blood clot, formed in the hemostatic phase, contains platelets and a specific kind of leukocytes, 
called neutrophils. Both components release several factors that enhance aggregation response, start 
the coagulation cascade and function as chemoattractants in the inflammation. A few hours after 
injury, the neutrophils in the blood cross the blood capillaries’ wall of endothelial cells and thereby 
enter the wound (reviewed by Eming et al., 2007; Woodfin et al., 2010). At the wound site the 
neutrophils initiate the removal of damaged tissue and phagocytosis of agents that may infect the 
wound (reviewed by Eming et al., 2007). 
Two days after injury macrophages appear at the wound site and they terminate the infiltration of 
neutrophils by initiating a phagocytosis of the neutrophils. The presence of the macrophages at the 
wound site is due to growth factors and cytokines (reviewed by Eming et al., 2007). The 
macrophages secretes essential growth factors, like transformation growth factor- β (TGF-β), 
transformation growth factor- α (TGF-α), platelet derived growth factor (PDGF), vascular 
endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) (reviewed by Eming et 
al., 2007). In the skin, these growth factors increase the proliferation of the cells and the 
establishment of molecules in the extracellular matrix (ECM) (reviewed by Eming et al., 2007) 
(Fig. 2.5).   
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Fig. 2.5 The inflammatory phase and proliferative phase. Inflammatory phase: The macrophages infiltrate 
the wound. The proliferative phase: migration of epithelial cells, granulation formation and angiogenesis 
(modified from Gurtner et al., 2008). 
 
2.2.4 THE PROLIFERATIVE PHASE 
Three different overlapping processes characterize the proliferative phase: reepithelialization, 
fibroplasia and angiogenesis (Fig. 2.5). The proliferative phase is overlapping with the 
inflammatory phase and the remodeling phase (Fig. 2.2) (reviewed by Li et al., 2007).  
 
Reepithelialization is a process that starts within a 24 hours of injury (reviewed by Li et al., 2007). 
The aim is to restore the epidermis by epidermal keratinocyte migration and proliferation, which are 
stimulated by epidermal growth factor (EGF), TGF-α, fibroblast growth factor (FGF) and 
keratinocyte growth factor (KGF). These stimulating growth factors are produced among others in 
platelets, macrophages, fibroblast, keratinocytes and in endothelial cells (reviewed by Li et al., 
2007; Barrientos et al., 2008). The first step in reepithelialization is keratinocyte migration. The 
keratinocytes migrate from unwounded epidermis surrounding the wound, into the wound 
(Engelhardt et al., 1998; Laplante et al., 2001). During reepithelialization there is an increased 
proliferation of keratinocytes, which guarantee a correct amount of cells to migrate. When a 
monolayer of keratinocytes covers the entire wound, the migration stops and the rate of the 
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proliferation is reduced (Hunt et al., 2000; reviewed by Li et al., 2007). A production of new 
epidermis begins, due to keratinocyte differentiation. The wound closes when 100% 
reepithelialization is reached (Barrientos et al., 2008). 
 
Fibroplasia is a process that contributes with proliferation and migration of fibroblasts into the 
wound (reviewed by Li et al., 2007). The process is at first stimulated by cytokines which are 
secreted by macrophages (reviewed by Laurens et al., 2006). Five days after the injury has 
occurred, migration of fibroblasts into the wound site initiates. The migration is triggered by 
especially the growth factors PDGF and TGF-β, fibrin and fibronectin, which also stimulates 
fibroblast proliferation (reviewed by Laurens et al., 2006). At the wound site there has been 
established a blood clot of fibrin, but the fibroblasts form collagen and other ECM proteins, which 
the fibrin is substituted with (reviewed by Laurens et al., 2006). The establishment of collagen and 
ECM proteins contribute to the production of granulation tissue (reviewed by Li et al., 2007). 
In the proliferative phase there are plentiful of myofibroblasts which begin to appear in the early 
phase of the granulation tissue formation (reviewed by Li & Wang, 2011). Seven days after injury, 
fibroblasts differentiate into myofibroblasts, which then can differentiate into smooth muscle cells. 
Myofibroblasts contract so that the wound size is reduced (reviewed by Li & Wang, 2011). 
 
Angiogenesis is the formation of new capillary blood vessels. The new capillary sprouts from 
preexisting micro-vessels adjacent to the wound, and thereby supply the wounded area with the 
appropriate blood (reviewed by Battegay, 1995; reviewed by Li et al., 2007). These newly formed 
vessels main functions is to assist in the removal of dead or damaged tissue, sustaining of cell 
metabolism and the development of granulation tissue framework. Furthermore, the new capillary 
blood vessels deliver nutrition and oxygen to the injured cells, transport  inflammatory cells into or 
out of the injured area, and dead or damaged tissue out of the wound (reviewed by Battegay 1995; 
Nissen et al., 1998; reviewed by Laurens et al., 2006). 
Angiogenesis is activated by potent direct angiogenic factors, such as fibroblast growth factor-2 
(FGF-2) and VEGF (Nissen et al., 1998). The process begins when the endothelial cells migrate into 
the dermis and start to proliferate by forming new capillary tubes (reviewed by Laurens et al., 
2006). FGF-2 initiates wound angiogenesis by stimulating the endothelial cell proliferation. FGF-2 
is released shortly after the tissue injury (Nissen et al., 1998). According to Nissen et al. (1998) 
VEGF is produced when the level of FGF-2 is lowered and may play a role in angiogenic stimulus 
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in wounds, either by having a direct effect on proliferation and migration of endothelial cells or by 
indirectly effecting the level of vascular permeability and differentiation of the pre-existing small 
vessels (reviewed by Laurens et al., 2006). 
 
2.2.5 THE REMODELING PHASE  
The remodeling phase is contemporary with the hemostatic phase, the inflammatory phase and the 
proliferative phase. In this phase the granulation tissue, formed in the proliferative phase, is 
replaced by scar tissue (reviewed by Li et al., 2007). Fibroblasts, neutrophils and macrophages in 
the wound produce matrix metalloproteinase enzymes (MMP), which break down collagen 
(reviewed by Velnar et al., 2009). Inhibitory factors regulate the MMP activation; these inhibitors 
are increased in the remodeling phase, which means that the accumulation of new cellular matrix is 
promoted. An interaction between fibroblasts and cellular matrix, caused by the factors PDGF, 
TGF-α and FGF , brings the wound edges closer together, and thereby reduces the wound size 
(reviewed by Velnar et al., 2009). Apoptosis reduces the concentration of macrophages and 
fibroblasts with time. The remodeling phase can last up to one or two years and the final result is 
formation of scar tissue. The scar tissue contains a lot of collagen, a decreased number of cells and 
blood vessels compared to unwounded skin (Fig. 2.6) (reviewed by Velnar et al., 2009). 
 
Fig. 2.6 Wound healing during the remodeling phase. Scar tissue replaces granulation tissue, collagen levels 
are increased, the amount of cells and blood vessels are decreased. The wound is now fully healed (Modified 
from Gurtner et al., 2008). 
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2.3 MICRORNA 
miRNA is a small, non-coding, endogenous, single-stranded RNA molecule, which is about 
22 nucleotides (nt) in length. miRNA is capable of posttranscriptional gene regulation by binding 
to specific target mRNAs, with a complementary sequence, suppressing the mRNA translation or 
targeting the mRNA for degradation and thereby inhibiting the expression of a specific gene. 
Research has suggested that miRNA perform gene regulation during skin development (reviewed 
by Banerjee et al., 2011; Phillips et al., 2014). 
 
 
Fig. 2.7 1. The formation of miRNA, from its origin as a part of a precursor RNA in the nucleus. 2. Drosha 
processing and Exportin 5 export from the nucleus to the cytoplasm. 3. Dicer processing in the cytoplasm 4. 
Separation of strands. 5. Composition of RNA-induced silencing complex. 6. mRNA translational 
repression (Bouasker & Simard, 2009). 
miRNA is made from a precursor RNA molecule which is folded back on itself, creating hairpin 
structures (Reece et al., 2011). Polymerase II and III transcribe primary miRNA transcripts (pri-
miRNA) into precursor miRNA (pre-miRNA) (Ender & Meister, 2010). Pri-miRNA locus is found 
in introns, untranslated regions or in intragenic regions. miRNAs are commonly found in clusters or 
as a part of one whole transcript (Mayer, 2010).  
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A microprocesser complex consisting of RNase III enzyme Drosha and DiGeorge syndrome critical 
region gene 8 (DGCR8) cofactor, processes pri-miRNA in the nucleus; the pri-miRNA is cleaved at 
the stem of the hairpin creating a pre-miRNA (Fig. 2.7) (Ender & Meister, 2010). DGCR8 marks 
the single-stranded segments of the pri-miRNA, thereby determining where the cleavage by Drosha 
is to take place. The distance from the DGCR8 mark to the cleavage of Drosha is exactly 11 bp long 
and is the shortest length that an RNase III enzyme is able to process (Carthew & Sontheimer, 
2010).  
The pre-miRNA is then exported by the export receptor exportin-5 (Mayer, 2010) from the nucleus 
to the cytoplasm (Ender & Meister, 2010). In the cytoplasm the pre-miRNA is further processed by 
the RNase III enzyme, Dicer. Dicer cleaves the pre-miRNA, in both ends, creating a double-
stranded 22 nt RNA with 5’-phosphates and 2-nucleotide 3’ overhangs (Ender & Meister, 2010). 
5’-phosphates are the phosphate groups attached to the 5’ end and the 2-nucleotide 3’ overhangs, 
meaning that two nucleotides (adenine) at the 3’ end are unpaired, and are therefore “overhangs” at 
the end of one of the strands (Mayer, 2010). One of the strands of the double-stranded pre-miRNA 
is degraded and the other miRNA strand is then released. The miRNA hereafter arranges itself in a 
complex with one or more proteins, termed a RNA-induced silencing complex (RISC) (Hammond 
et al., 2000). RISC and miRNA are capable of binding to a target mRNA, which contains seven or 
more bases of complementary sequences (Reece et al., 2011), also known as the seed sequence 
(reviewed by Banerjee et al., 2011). The target specificity of the miRNAs is determined by the seed 
sequence, and miRNAs can have over 100 targets and more than half or every mRNAs are known 
to be targets (reviewed be Gurtan & Sharp, 2013).  
The mRNA silencing depends on the complementarity between miRNA and its target mRNA. If the 
complementarity is perfect between the two factors, endonucleolytic cleavage takes place and 
thereby the mRNAs translation is blocked. If the complementarity is imperfect, the gene 
information carried by the mRNA is repressed, during the phase of translation (Pillai et al., 2007) 
due to the miRNA and RISC physically blocking the translation (Phillips et al., 2014). The reason 
for the two different outcomes of miRNA’s gene silencing can be explained through Argonaute 
(Ago) proteins. 
Besides the miRNA, the main component of RISC is the Ago protein (Liu et al., 2004). The Ago 
protein is a crucial element in RISC and thus to the gene silencing of mRNA (Ender & Meister 
2010).  
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The Ago protein contains and executes the Slicer activity, which is the catalytic activity of RISC 
(Liu et al., 2004). The Ago protein is formed by a PIWI-Argonaute-Zwille (PAZ) domain, a  P-
element induced wimpy testis (PIWI) domain (Ender & Meister, 2010), a middle (MID) domain and 
the amino-terminal (N) (Bouasker & Simard, 2009; Mayer, 2010). 
The 5’ end of the miRNA string is bound to the Ago protein and anchored to the MID domain by 
the Ago protein (Fig. 2.8). The PAZ domain binds to the 3’ end and it may play a vital role in 
miRNA, due to its ability to recognize the 2-nucleotide 3’ overhangs of the miRNA (Mayer, 2010).  
 
 
Fig. 2.8 A: The 5’-phosphate is anchored to the MID domain and the 2 nucleotide 3’ end overhang to the 
PAZ domain. B: Base pairing occurs between miRNA and mRNA, initiating at the 5’-phosphate end, 
allowing a double helix to be formed. C: While both 5’ and 3’ is still firmly attached to their domains, the 
helix is prolonged. The 3’ is thereafter released from the PAZ domain. D: The mRNA is now positioned 
correctly for cleavage which is performed by Magnesium ions in the PIWI domain (Bouasker & Simard, 
2009). 
The Ago protein cleaves the targeted mRNAs when the miRNAs complementarity to the mRNA is 
perfect. In most mammalians the miRNAs and the mRNAs sequences are only partially 
complementary and the slicer-activity of the Ago protein is therefore infrequently preformed 
(Mayer, 2010). Thus in mammalians the Ago proteins function is to assist the miRNA in binding to 
its target mRNA and thereby assisting in blocking the translation of the targeted mRNA (Bouasker 
& Simard, 2009). 
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The methods used in this project are based on a literature review and a scientific experiment. The 
literature review is utilized in order to answer the theoretical part of the problem of interest; the 
processes involved in wound healing and furthermore a description of diabetes and miRNA. The 
base of the literature review is scientific articles and educational books. 
The purpose of this project’s experiment is to determine the relative amount of specific miRNA in 
wounded mouse skin. The skin samples were derived from 12 normal/healthy C57BL/7 mice (wt). 
Six of the mice were treated with a daily intraperitoneal (i.p.) injection of 50 mg/kg streptozotocin 
(STZ) in 200 µl citrate buffer, with a pH 4.2, for 5 days. STZ is poison for the β-cells, so when the 
β-cells of the mice are exposed to STZ, the cells begin to degrade and in this way, the mice develop 
diabetes. The remaining six mice have not been exposed to any treatments. On the back of the 12 
anesthetized mice, two 6 mm excision wounds were created, on the six mice treated with STZ, the 
excision wounds were created 4 weeks after treatment with STZ. In the experiment of this project, 
three skin samples from each mouse were utilized. The three skin samples were from day 0, day 3 
and day 10 after wound excision, respectively. 
The experiment of this project is divided into three steps: 
1.      Homogenization 
2.      Purification of RNA 
3.      Microarrays 
·         Synthesis of cDNA 
·         qPCR 
 
3.1 HOMOGENIZATION 
In the first part of the experiment, all 36 skin samples were homogenized. The purpose of 
homogenization is to make a homogenous mixture so that the RNA molecules are released thus the 
RNA can be isolated for further analysis. 
Tweezers, scissors and a homogenizer were cleaned with RNase Decontamination Solution 
(RNAseZAP) which degrade the enzymes RNAses, that otherwise would break down the wanted 
RNA. One ml of TRI Reagent (RNA Isolation Reagent, Sigma-Aldrich) was transferred to a 
3. METHODS AND MATERIALS 
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polypropylene tube. TRI Reagent was used to isolate RNA and furthermore it inhibits RNase. 
Afterwards, a skin sample was cut into small pieces and they were then transferred into the 
polypropylene tube with one ml of TRI Reagent. Then, the mixture of skin and TRI Reagent was 
homogenized for approximately 1 minute. Skin pieces were then cleaned off the homogenizer with 
tweezers and thereafter the pieces were put back into the polypropylene tube. The process was 
repeated 2-3 times. After the homogenization the mixture was transferred to a labeled eppendorf 
tube and was subsequently placed on ice. The homogenizer was cleansed again for skin pieces with 
tweezers and then rinsed in Diethylpyrocarbonate water 2-3 times, until the homogenizer was 
completely free of skin. Finally, the samples were placed in a labeled box in the freezer at -80 ˚C 
until further analysis. 
 
3.2 PURIFICATION OF RNA 
The purpose of this experiment was to isolate and purify the RNA of the mice skin samples. This 
was done by separating the RNA from the DNA and the proteins, according to manufacturer's 
protocol for isolating RNA with TRI Reagent. The concentration and the quality of the samples 
were measured using NanoDrop1000 (Thermo Fisher Scientific Inc). 
First step was to thaw the sample; afterwards 1.5 µl spike-in (cel-miR-39, 1 pmol/µl) was added and 
briefly whirl-mixed. The spike-in can be used to quality control the RNA isolation and cDNA 
synthesis steps. Next, 200 µl chloroform was added to the sample and the solution was whirl-mixed 
in 15-20 seconds. Chloroform contributes to establish three phases which occurs after 
centrifugation. The solution rested for a couple of minutes, before it was centrifuged at 12,000 x g 
for 15 minutes at 4˚C. Afterwards the solution consisted of three phases, an aqueous phase of RNA, 
a cloudy interphase of DNA and a pink organic phase of proteins. The aqueous phase containing 
RNA was transferred to an Eppendorf-tube containing 500 µl isopropanol. Isopropanol makes a 
precipitate of the RNA. The solution was whirl-mixed before it rested for 10 minutes. Then the 
solution was centrifuged for 10 minutes at 12,000 x g and 4˚C. After centrifugation, the solution 
was poured out, and hereafter 1 ml 75 % ethanol was added to the Eppendorf-tubes in order to rinse 
the RNA pellet, which is created by the isopropanol. 
The solution was observed for RNA-pellet, and then the solution was whirl-mixed and subsequently 
centrifuged for 5 minutes at 12,000 x g and 4˚C. When the centrifugation was done, the ethanol was 
poured out and the pellet air-dried for 10 minutes. Resuspension of the RNA pellet in 40 µL DEPC-
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water and the RNA pellet was dissolved by pipetting up and down. All of the samples were 
transferred to another labelled Eppendorf-tube. Then finally, the RNA concentration and 
purification of the samples were measured by Nanodrop1000 (Appendix A, Table 7.1) 
 
3.3 MICROARRAY 
Microarray is a method divided into two smaller experiments: complementary DNA (cDNA) 
synthesis, from the RNA template, which was first isolated and purified. The other experiment was 
quantitative polymerase chain reaction (qPCR), where the threshold cycle (Ct) value for every 
miRNA in the skin of the mice is detected. The RNA concentrations measured on Nanodrop1000 
differed a lot, and therefore the samples were diluted with nuclease-free water, so the RNA 
concentration of all the samples was 200 ng/µl. From every sample, with the purified RNA, 2 µl 
was transferred to a pool, which then contained 12 µl. The samples were divided into six pools; one 
pool contained all samples from day 0 with wt mice, and one with samples from day 0 with wt STZ 
mice. Two pools with all samples from day 3, one with wt mice and one with wt STZ mice. Then at 
last there were two pools with samples from day 10, one with wt mice and the last one with wt STZ 
mice. The total concentration of RNA in one pool was 600 ng per pool, due to the removal of 3 µl 
with a concentration of 200 ng/µl. The total amount of RNA was in the range of 350 to 1000 ng, 
and therefore the Megaplex pools, pool A and B, were run without pre-amplification.  
 
3.3.1 COMPLEMENTARY DNA 
The purpose of the reverse transcription (RT) reaction was to synthesize cDNA from a RNA 
template. For the synthesis of single-stranded cDNA, TaqMan MicroRNA RT Kit and Megaplex 
RT Primers were used. First, a 4.5 µl RT reaction mix was made; this was firstly done by thawing 
Megaplex RT primers, TaqMan MicroRNA RT Kit components and MgCl2 on ice. Then the 
following components were mixed in a tube: 0.8 µl Megaplex RT Primers (10X), 0.2 µl dNTPs 
with dTTP (100 mM), 1.5 µl MultiScribe Reverse Transcriptase (50 U/µl), 0.8 µl 10X RT Buffer, 
0.9 µl MgCl2 (25 mM), 0.1 µl RNase Inhibitor (20 U/µl), and 0.2 µl Nuclease-free water. 
The function of the Megaplex RT Primer is to bind to the complementary sequence on the 3’ end of 
the RNA template, and thereby start the cDNA synthesis (Fig. 3.1). 
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Fig. 3.1 RT reaction; Looped RT primer, also called Megaplex RT primer binds to the RNA template, 
hereafter the DNA polymerase starts DNA replication and thereby synthesis of cDNA (Appliedbiosystems, 
2010). 
 
Reverse transcriptase is an enzyme, which function was to transcribe the RNA template into the 
cDNA. This was done by adding the nucleotides dNTP with dTTP to the 3’ end of the new DNA 
strand. Before reverse transcriptase catalyzed the synthesis of cDNA, MgCl2, which is a cofactor 
necessary for the activation of reverse transcriptase, was added. The function of the 10 X RT buffer 
was to sustain a specific pH. The RNase inhibitor made sure that the RNA did not break down. The 
last component, which was the nuclease-free water, was used to achieve the wanted volume of the 
RT reaction mix (Reece et al., 2011).  
All these components were then mixed, by inverting the tube six times and then subsequently 
centrifuged briefly. The 4.5 µl RT reaction mix was then added to a MicroAmp 8-Tube Strip, 
hereafter 3 µl (600 ng) total RNA, from the pool, was added to the tube that contained the RT 
reaction mix. Then the tube was sealed with an Optical Strip Cap, afterwards it was mixed by 
inverting it six times and then it was spun briefly, hereafter it rested on ice for 5 minutes. This was 
done for all the six pools.  
Before running the plate on GeneAmp PCR System 9700 a few conditions had to be set. The ramp 
speed was set to Max ramp speed, which indicated the rate at which the temperature of the reaction 
was achieved. Furthermore the reaction volume was 7.5 µl and the thermal-cycling conditions were 
set to 2 minutes at 16°C, hereafter 1 minute at 42°C and at last 1 minute at 50°C; this cycle ran 40 
times. Furthermore there were two holds in the cycle, one at 85°C for 5 minutes and another at 4°C, 
where it potentially could stay infinitely. When the conditions were set, the RT reaction mix was 
loaded in a tube and hereafter the tube was run. Hereafter the cDNA synthesis is completed.  
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3.3.2 QUANTITATIVE-REAL TIME POLYMERASE CHAIN REACTION  
In qPCR the Ct values for every miRNA in the skin of the mice were detected. The Ct value shows 
the relative expression of the specific miRNA. A threshold was set to be 0.065, when the 
fluorescence passed this threshold the cycle number was equal to the Ct value. Ct values are 
reversely proportional to the expression of the miRNA, due to exponential growth, for instance 
when the Ct value rose with 1, the expression of the miRNA was reduced by half 
(Lifetechnologies). The TaqMan miRNA array was removed from its packaging after it had reached 
room temperature. On the TaqMan miRNA array there were sequence-specific primers and probes.  
Then a PCR reaction mix was made. The Megaplex RT product, which was the cDNA made from 
the experiment before, was thawed and hereafter mixed by inverting the tube six times. Then the 
TaqMan PCR master mix, No AmpErase UNG, 2X, which contained DNA polymerase, was spun. 
Hereafter 6 µl of the Megaplex RT product, 450 µl of the TaqMan PCR master mix and 444 µl 
nuclease-free water was mixed in a tube, by inverting it six times and thereafter centrifuged briefly. 
At last the TaqMan miRNA Array was loaded by adding 100 µl, from the newly made PCR 
reaction mix, into each port of the Array. Hereafter the Array was centrifuged and then sealed. 
When the Array was loaded, it was placed in Viia 7, which ran the Array using 384-well TaqMan 
low density array default thermal-cycling conditions. These thermal-cycling conditions were 15 
seconds at 95
o
C and 1 minute at 60
o
C, which ran 40 times. Then there were two holds, one at 50
o
C 
for 2 minutes and one at 95
o
C for 10 minutes (Fig. 3.2).     
 
Fig. 3.2 Thermal cycle conditions. 15 seconds at 95
o
C and 1 minute at 60
o
C, this cycle runs 40 times. There 
were two holds: one for 2 minutes at 50
 o
C and one at 9
 o
C.  
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In every cycle the same steps took place: the sequence-specific primers bound to the cDNA 
template, hereafter a TaqMan probe could bind to a complementary sequence, between the forward 
and the reverse primers. The TaqMan probe contained a reporter on the 5’ end and a non-
fluorescent quencher at the 3’ end, when the TaqMan probe was intact there was no fluorescence 
due to the quencher. When DNA polymerase, from the TaqMan PCR master mix, extended the 
primers, the probes bound to the cDNA template were cleaved. When the probe was cleaved, the 
quencher and the reporter were separated, which resulted in fluorescence of the reporter. Because 
the probes were sequence-specific, the fluorescence signal was a sign of how much of the specific 
miRNA was expressed (Fig. 3.3).             
 
 
 
Fig. 3.3 Nuclease activity of the DNA Polymerase system from 5’ end to 3’ end. The TaqMan probe binds to 
a complementary sequence on the cDNA template. The probe contains a reporter R and a quencher Q. When 
the probe is cleaved, fluorescence of the reporter is activated; thereby fluorescence is a sign of the relative 
miRNA expression (protocol) 
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Data processing of the threshold cycle data 
The Ct values of the selected miRNAs were used to calculate how many times the relative 
expression of miRNA was increased or decreased in the different kinds of skin samples using the 
comparative Ct method, also known as the 2
-∆∆Ct
 method.  
The data set of the Ct values contained data from four reference genes called U6 snRNA. The 
geometric mean of the Ct values of these genes was calculated. In Excel, the function GEOMEAN 
was used for this calculation (Appendix B, Table 7.3). 
When the geometric means were calculated, the ΔCt values were determined by subtracting the 
geometric mean from the Ct values of the miRNAs. This was done in order to normalize the data. 
There was a Ct value for day 0, 3 and 10 for each of the wt mice and for each of the wt STZ mice. 
An example of a ΔCt calculation, miR-133a, wt STZ, day 3: 
 
                                              (3.1) 
  
Next, the ΔΔCt values were determined by subtracting the control ΔCt value from the ΔCt. The ΔCt 
values of the day 0 wt mice were used as control for the other wt mice. The ΔCt values of day 0 of 
the wt STZ mice were used as control for the wt STZ mice. 
An example of a ΔΔCt calculation of miR-133a, wt STZ, day 3: 
 
          (     )       (             )                     (3.2) 
 
All the calculated ΔΔCt values were multiplied by -1. Hereafter, it was possible to determine the 
fold change of all the miRNAs, i.e. how much the relative expression of miRNA is increased or 
decreased in the sample normalized to U6.  
An example of a fold change calculation of miR-133a, wt STZ, day 3:  
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                                   (3.3) 
 
This fold change showed that on day 3, the miRNA was decreased compared to the relative 
expression which was present on day 0. All the controls had a fold change, which was equal to 1. If 
the fold change was below 1, the miRNA was decreased, and if the fold change was above 1, the 
miRNA was increased compared to day 0.  The calculated fold changes were used to compare the 
miRNA increase or decrease of day 0, 3 and 10 within the same phenotype, but not how much the 
miRNA was increased or decreased in a comparison of the wt mice and the wt STZ mice. To 
determine this ratio, another set of fold changes were calculated. Instead of using the ΔCt value of 
day 0 wt STZ mice as control for the calculation of the ΔΔCt of the wt STZ mice, the ΔCt value of 
day 0 wt mice was used. 
An example of a ΔΔCt calculation and a fold change calculation of miR-133a, wt STZ, day 0: 
 
          (     )       (             )                      (3.4) 
                      (     )          (3.5) 
 
The fold change indicated that the relative expression of miRNA was 9.3 times increased in the wt 
STZ mice compared to the wt mice on day 0. 
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4.1 SORTING OF MIRNAS 
Because the samples of the mice were divided into pools, it has not been possible to make statistical 
calculations and therefore all the calculated results are shown as the relative expression of each 
miRNA compared to a control sample. 
There were only chosen ten miRNAs out of 768. This was done, because it was not possible to 
analyse and discuss all 768 miRNAs. There had to be a limit, and therefore there was selected 10 
miRNAs. This limit meant that a lot of miRNAs were not selected, and therefore there were some 
interesting miRNAs that were deselected but some miRNAs were selected on basis of their 
influence on wound healing according to present research, and they will be discussed later. The ten 
chosen miRNAs were chosen on the basis of their measured Ct values and calculated fold changes. 
Ct values of all 768 miRNAs, 384 in Array A and 384 in Array B, were measured for day 0, day 3 
and day 10 for both wt mice and wt STZ mice. All the Ct values were sorted according to ascending 
Ct values. For each day, there was a selection of the miRNAs with Ct values below 30, one of these 
were allowed to be a little over 30 for each miRNA. This limit was chosen because the Ct values are 
reversely proportional to the relative expression of product, i.e. the relative expression of miRNA. 
When the Ct values are above 30, the relative expression of miRNA is very low or there is not any 
miRNA present. Out of the 768 miRNAs, the wt mice had 134 miRNAs with Ct values below 30 on 
day 0, i.e. 134 miRNAs were expressed on day 0. This signifies that there were 634 miRNAs that 
were not expressed particularly or not at all on day 0.  Furthermore, 133 and 169 miRNAs of the wt 
mice were expressed on day 3 and day 10, respectively. In the wt STZ mice, the numbers of 
expressed miRNAs were decreased a lot on day 0. Out of 768 miRNAs, 39 miRNAs had Ct values 
below 30 on day 0, 144 miRNAs were expressed on day 3 and 134 miRNAs were expressed on day 
10.  All the expressed miRNAs from each day and each phenotype were gathered in a Venny 
diagram.  
4. RESULTS 
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Fig. 4.1 A Venny diagram of miRNAs of the three different days. All the miRNAs had Ct values below 30. 
The numbers indicates how many miRNAs the days had in common. 36 miRNAs were common to all three 
days. 5, 0, 21, 1, 5 and 2 miRNAs were only common to day 0 wt, day 3 wt, day 10 wt, day 0 wt STZ, day 3 
wt STZ and day 10 wt STZ, respectively. 
Fig. 4.1 shows which miRNAs that were common throughout the days. 36 miRNAs were common 
on all of the days, meaning that on all three days for wt mice and wt STZ mice the same 36 
miRNAs were expressed (Appendix B, Table 7.7).  Additionally, specific miRNAs were expressed 
in the wt STZ mice but not in the wt mice and vice versa. Eight miRNAs were only expressed in the 
wt STZ mice (Appendix B, Table 7.8). Fig. 4.1 also shows that 26 miRNAs were only expressed in 
the wt mice. On day 0 in the wt mice, five miRNAs were the only miRNAs that were expressed 
while the last 21 miRNAs were expressed on day 10 (Appendix B, Table 7.8). 
 
 
 
 
Page 28 of 69 
 
4.2 SELECTION OF THE MIRNAS 
The final ten miRNAs were chosen after specific criteria; they had to have at least a fold change 
which was above two, and hereafter the miRNAs were chosen after how high the fold change ratios 
between the wt mice and wt STZ mice were. A few of the miRNAs with a high fold change had 
also a very low fold change on one of the other days, and this showed a decrease in the relative 
expression of miRNA on that specific day.      
 
Fig. 4.2 Array A: The bar chart shows the relative expressions of the 25 miRNAs which all three days had Ct 
values below 30. The relative expression is normalized to the U6-gene. On the x-axis the relative expressions 
are seen and the miRNAs are seen on the y-axis. The selected miRNAs are marked with a red frame.   
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Fig. 4.3 Array B: The bar chart shows the relative expressions of the 12 miRNAs which all three days had Ct 
values below 30. The relative expression is normalized to the U6 On the y-axis the miRNAs are seen and the 
relative expressions are seen on the x-axis. The selected miRNAs are marked with a red frame.  
The following miRNAs were chosen: 
- miR-126-3p 
- miR-133a 
- miR-191 
- miR-193b 
- miR-320 
- miR-342-3p 
- miR-574-3p 
- miR-150 
- miR-1937c 
- miR-1937b 
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Almost all the selected miRNAs had just one day with a fold change that was greater than two. On 
day 0, the miRNAs miR-126-3p, miR-191, miR-193b, miR-320, miR-342-3p and miR-574-3p had 
fold changes higher than 3 (range 3.1-6.1) (Fig. 4.2). miR-133a had two fold changes which were 
above two. On day 0 the fold change was 9.3, and three days after injury the fold change was 2.1 
(Fig. 4.2).  
On day 3, the fold change of miR-1937c was 2.1 and miR-1937b had a fold change of 51.9. The 
fold changes of miR-1937c and miR-1937 b, on day 0, was 0.04 and 0.2, respectively (Fig. 4.3).   
A lot of miRNAs were not selected because of their fold changes were too close to being equal to 1. 
For example, miR-203 was not chosen, because the fold changes of the miRNA were 0.7 on day 0, 
1.5 on day 3 and 0.6 on day 10 (Fig. 4.2). These fold changes showed that there was not a notable 
increase or decrease in the relative expression of miR-203 compared to some of the other miRNAs, 
which were greatly increased or decreased. miRNAs with a higher increase or decrease in their 
expression would probably have a more notable impact on the wound healing processes than 
miRNAs with a smaller increase or decrease and therefore be more interesting to examine. 
miR-150 was selected, even though it had one Ct value that was above 30, approximately 30.6 
(Appendix B, Table 7.2). miR-150 was first and foremost chosen on the basis of its high fold 
change ratio between the wt mice and the wt STZ mice, which was 4.1 on day 3 (Appendix B, 
Table 7.6). miR-150 had only one Ct value above 30, which just exceeded with 0.6, and therefore an 
exception was made.  
All the chosen miRNAs, except miR-150, had a Ct value below 30 in all six samples. This means 
that all the miRNAs were expressed each day, and therefore it was only possible to see how much 
each chosen miRNA was increased or decreased on each particular day. An increase or decrease of 
a specific miRNA can influence the synthesis of certain proteins that are important in the wound 
healing process. It is not only an increase or decrease of the specific miRNA that may impair the 
wound healing. When the miRNA is not expressed, it cannot exercise its function. If the function of 
the miRNA was to inhibit the production of a specific protein, this protein may affect the wound 
healing. Additionally, if the function was to stimulate the synthesis of a specific protein, the protein 
may not be synthesized, and a possibly important protein in one of the phases of the wound healing 
would be missing. Hereby, the wound healing would be impaired, but it could also be stimulated if 
the protein missing has an inhibiting impact on wound healing. With all this in mind, it could have 
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been interesting to have selected a miRNA that were expressed in the wt mice but not in the wt STZ 
mice, or a miRNA that were not expressed in the wt mice but were in the wt STZ mice. miR-1193 
had on day 0 of the wt STZ mice a Ct value of 24.1 (Fig. 4.1) (Appendix C, Table 7.9). The Ct value 
of day 0 in the wt mice was undetermined, which means that miR-1193 was possibly not 
particularly expressed or not at all in the wt mice on day 0. 
4.3 DATA DESCRIPTION 
For simplicity, the fold changes are round off. For the complete number see Appendix B, Table 7.4, 
7.5 and 7.6.  
 
Fig. 4.4 The relative expression of the ten chosen miRNAs in the wt mice. Each miRNA have three bars 
showing the fold change for each day: day 0, 3 and 10. The control was day 0 of the wt mice, which had a 
fold change equal to 1.   
Fig. 4.4 shows the fold changes of the ten chosen miRNAs, in the wt mice. All of the fold changes 
from day 0 were used as controls, and were therefore equal to 1. Fig. 4.4 shows which miRNAs that 
were relatively increased or decreased compared to day 0, in the wt mice, of the different days. For 
instance, the relative expression of miR-126-3p was increased on both day 3, by  a fold change of 
1.52 and on day 10, by a 1.22 fold change, compared to day 0 (Fig. 4.4). 
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The miRNAs that were increased on both day 3 and day 10 were miR-126-3p, miR-191, miR-320 
and miR-342-3p by a fold change up to 1.5 on day 3 and a fold change up to 1.7 on day 10. miR-
133a, miR-193b and miR-150 were increased by a fold change up to 2.4 fold on day 3 but decreased 
by a fold change between 0.95 and 0.70 on day 10. The miRNAs that were decreased on day 3, but 
increased on day 10 were miR-1937c and miR-1937b by a fold change of 0.9 in both miRNAs on 
day 3 and by a maximum fold change of 1.27 fold on day 10. Finally, miR-574-3p was decreased 
on both day 3 and day 10 by a fold change of 0.88 and by a fold change of 0.4 respectively 
(Appendix B, Table 7.4) (Fig. 4.4). 
 
Fig. 4.5 The relative expression of the ten chosen miRNAs in the wt STZ mice. Each miRNA has three bars 
showing the fold changes for each day: day 0, 3 and 10. The control was day 0 of the wt STZ mice, which 
had a fold change equal to 1.    
Fig. 4.5 shows the fold changes, for each of the ten miRNAs, of the wt STZ mice. The control was 
day 0 of the wt STZ mice. Fig. 4.5 shows the different fold changes of all the miRNAs, on day 3 
and 10 compared to day 0. The miRNAs that were increased on both day 3 and day 10 were miR-
1937b and miR-1937c, by up to 24.8 folds on day 3 and up to 18.7 folds on day 10. miR-150 was 
increased on day 3 by 2.26 fold but decreased, by 2.2 folds, on day 10. The remaining miRNAs: 
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miR-574-3p, miR-342-3p, miR-320, miR-193b, miR-191, miR-133a and miR-126-3p were 
decreased, by 90 % and less, on both day 3 and day 10 (Appendix B, Table 7.5) (Fig. 4.5).  
By comparing the data from Fig. 4.4 and Fig. 4.5, it is shown that miR-1937b of the wt STZ mice 
was greatly increased on day 3 by a fold change of 5.28, but decreased on day 3 in the wt mice by a 
fold change of 0.94 on day 3 compared to day 0. This fold change was very close to 1, and was 
therefore not a notable change. Nevertheless, this fold change still signifies that the amount of miR-
1937b was decreased in comparison of the wt mice on day 0. 
The relative expression of miR-1937c was in the two types of mice very different. In the wt STZ 
mice, miR-1937c had a fold change of 19.7 on day 10 and on day 3 it had a fold change of 25.76 
(Fig. 4.5). Indicating a high increase in the expression of miR-1937c, in the wt STZ mice, on both 
day 3 and day 10 compared to day 0 of the wt STZ mice. Whereas, in the wt mice, there was a 
decrease by a fold change of 0.96 on day 3 and an increase by a 1.27 fold change on day 10 
compared to day 0 of the wt mice (Fig. 4.4). This signifies that the change of the relatively 
expression of miR-1937c was not notable on day 3 and had a very little change on day 10 in the wt 
mice.  
It could be observed that, when comparing Fig. 4.4 and Fig. 4.5, the two different groups: the wt 
STZ mice and the wt mice were opposite, on day 3. The miRNAs were all except for miR-1937b, 
miR-1937c, miR-574-3p and miR-150, increased on day 3 of the wt mice, while they were 
decreased in the wt STZ mice on day 3. miR-1937b and miR-1937c were increased in the wt STZ 
mice by a fold change up to 25.76 and decreased in the wt mice by a fold change less than 0.96 on 
day 3. miR-574-3p was decreased in both types of mice, by  a fold change less than 0.9 and miR-
150 was increased in both types of mice by a fold change of 3.2 in the STZ mice and a fold change 
of 1.1 on day 3 (Appendix B, Table 7.4, 7.5). 
However, these figures were not efficient in comparing the two different groups of mice. These data 
only indicated which miRNAs that were increased or decreased in the two separate groups of mice, 
compared to day 0. For comparing the two types of mice, they would need the same control. 
Therefore, new calculations of the fold changes were made, as mentioned earlier in this report. In 
these new calculations, day 0 the wt mice were used as control for every miRNA in both the wt STZ 
mice and the wt mice. Thus, the fold changes shows the relatively expression of miRNAs of both 
the wt STZ mice and wt mice, compared to day 0 of the wt mice.  
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Fig. 4.6 The relative expression of the ten chosen miRNAs. Each miRNA has two bars showing the fold 
changes for day 0, in the wt STZ mice compared to the the wt mice day 0. The control was day 0 of the wt 
mice, which had a fold change equal to 1.    
Fig. 4.6 shows the fold changes of the ten chosen miRNAs on day 0, of the wt mice and the wt STZ 
mice. Day 0 of the wt mice were used as control. On day 0 of the wt STZ mice the miRNAs were 
all, except for miR-1937c and miR-1937b, increased by a fold change between 1.2 and 9.5, 
compared to the wt mice day 0. miR-1937c and miR-1937b, in the wt STZ mice, were the only 
miRNAs that were decreased on day 0, by a fold change of 0.04 and a fold change of 0.22, 
respectively (Fig. 4.6). 
 
0 1 2 3 4 5 6 7 8 9 10
miR-126-3p
miR-133a
miR-191
miR-193b
miR-320
miR-342-3p
miR-574-3p
miR-150
miR-1937c
miR-1937b
2-∆∆Ct  normalized to U6 
Fold changes of the ten miRNAs in wt mice & wt STZ 
mice (control wt day 0) 
Day 0 STZ Day 0 (control)
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Fig. 4.7 The relative expression of the ten chosen miRNAs. Each miRNA has three bars showing the fold 
changes for day 3, in the wt STZ mice and day 3 in the wt mice, compared to the wt mice day 0. The control 
was day 0 of the wt mice, which had a fold change equal to 1.    
The miRNAs on day 3 did not have a general pattern. All of the fold changes had a big variation 
between the two groups: the wt STZ mice and the wt mice, unlike day 0 and day 10, where the 
miRNAs showed a more general pattern. Fig. 4.7 show the fold changes of ten chosen miRNAs on 
day 3 of the wt mice and the wt STZ mice, compared to the wt mice day 0.  
The miRNAs that were increased, in both the wt STZ mice and the wt mice on day 3, were miR-
150, miR-126-3p, miR-133a and miR-191, by a fold change between 1.1 and 4.2. miR-1937c and 
miR-1937b was increased on day 3 in the wt STZ mice, by a fold change up to 2.5 and was both 
decreased, by a fold change of 0.9 in the wt mice on day 3. miR-193b, mir-320 and miR-342-3p 
were increased in the wt mice by maximum fold change of 1.3 and decreased by a change fold of  
2.5 or less in the wt STZ mice. miR-574-3p was decreased by fold change of 0.88 in the wt mice 
and decreased by a fold change of 0.41 in the wt STZ mice, on day 3. (Appendix B, Table 7.5, 7.6) 
(Fig. 4.7).  
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Fig. 4.8 The relative expression of the ten chosen miRNAs. Each miRNA has three bars showing the fold 
changes for day 10, in the wt STZ mice and day 10 in the wt mice compared to day 0 in the wt mice. The 
control was day 0 of the wt mice, which had a fold change equal to 1.    
Fig 4.8 show the ten miRNAs fold changes of the wt mice and the wt STZ mice on day 10, 
compared to the wt mice day 0. There was a more general pattern on day 10. It showed, except for 
miR-191, that every miRNA was decreased among the wt STZ mice by up to 5 folds. In the wt 
mice, the fold changes varied more; miR-150, miR-574-3p, miR-193b and miR-133a were 
decreased by up to 3 folds. While the miRNAs miR-1937c, miR-342-3p, miR-320, miR-191 and 
miR-126-3p were increased, by up to 0.77 folds (Fig. 4.8).  
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5.1 THE TEN MIRNAS IN RELATION TO WOUND HEALING 
Decrease or increase of several miRNAs influence wound healing by up- or down-regulating the 
expression of proteins that assist in wound repair or inhibit wound healing (Yi et al., 2008; Biswas 
et al., 2010; Chan et al., 2012
b
; Jin et al., 2013; van Solingen et al., 2014). 
 
miR-320 
Some of miR-320 targets’ are the proteins VEGF and fibronectin (Feng & Chakrabarti, 2012). The 
VEGF protein is secreted by macrophages in the inflammatory phase and is one of the growth 
factors that increase cell proliferation in the proliferative phase of wound healing. Furthermore the 
VEGF protein increases angiogenesis induction, vascular permeability, vasculogenesis, endothelial 
cell migration promotion and apoptosis inhibition (Genecards). Vasculogenesis is formation of new 
blood vessels derived from endothelial stem cells, when there are no pre-existing vessels (Maeda et 
al., 2008; Su et al., 2012). An up-regulation of miR-320 may results in decreased expression of the 
protein VEGF. This might indicate that cell proliferation in the proliferative phase is reduced, and 
that induction of angiogenesis and endothelial cell migration is impaired. New blood vessel 
formation might also be reduced when miR-320 is up-regulated. Apoptosis reduces the 
concentration of macrophages and fibroblast in the remodeling phase, so an up-regulation of miR-
320 might result in delayed macrophage and fibroblast reduction. The results of this experiment 
shows an up-regulation on day 3 and 10 of the wt mice compared to day 0, by a 1.3 and 1.8 fold 
change, respectively. The proliferative phase and the remodeling phase is after days to weeks, 
according to the theory VEGF is important on day 3 and 10 and therefore a down-regulation of 
miR-320 was expected. When comparing wt STZ mice with wt mice on day 0 there was a down-
regulation by a 0.8 and 0.7 fold change on day 3 and day 10, respectively, this might indicate that 
more VEGF is expressed among wt STZ mice on day 3 and day10.  
Fibronectin is also one of miR-320s’ targets and is important for host defense and blood coagulation 
in the hemostatic phase and for fibroblast migration and proliferation on the proliferative phase 
(Genecards). An up-regulation of miR-320 might result in reduced expression of fibronectin and 
thereby impaired blood coagulation, fibroblast migration and proliferation.  
As mentioned, the results of this project both showed an up-regulation on day 3 and 10 in wt mice 
4. RESULTS 5. ANALY IS & DISCUSSION 
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compared to day 0, this might indicate a reduced expression of fibronectin. This was not expected 
because fibronectin is important in the proliferative phase, days to weeks. Fibronectin is also 
important on day 0 in the hemostatic phase, but an up- or down-regulation on day 0 among wt mice 
was not examined in this report. Thought there was an up-regulation by a 5,6 fold change on day 0 
of wt STZ mice compared to wt mice on day 0, this could indicate that blood coagulation and 
thereby host defense is impaired among wt STZ mice. In wt STZ mice there were a down-
regulation on day 3 and 10 compared to wt mice on day 0, which might indicate that more 
fibronectin is expressed among wt STZ mice on day 3 and 10. 
It was not expected that both VEGF and fibronectin was more expressed in wt STZ mice on day 3 
and 10 than in wt mice, because they are important in the proliferative phase, days to weeks, and 
could be caused by other miRNAs and proteins that influence the wound healing processes.   
 
miR-191 
It has been demonstrated that an up-regulation of miR-191 increases cellular senescence and 
decreases proliferation in keratinocytes (Lena et al., 2012). miR-191 does so by targeting Special 
AT-rich Binding Protein1 (SATB1), whose down-regulation results in an increase of cellular 
senescence. miR-191 also targets Cyclin Dependent kinase 6 (CDK6), which is a positive regulator 
of cell cycle. Both CDK6 and SATB1 are in connection to keratinocytes (Lena et al., 2012). Thus 
an up-regulation of miR-191 could cause a decrease in cell cycle. The epidermis consists among 
others of keratinocytes. If a wound occurs, a part of the epidermis is damaged, and then the different 
phases of the wound healing initiate. In the reepithelialization, the epidermis is restored by 
epidermal keratinocyte migration and proliferation. In the wt STZ mice, miR-191 was increased by 
a fold change of 3.9 on day 0 compared to wt day 0. When miR-191 was increased in the wt STZ 
mice, the reepithelialization could have been impaired. miR-191 has possibly inhibited the 
proliferation of the keratinocytes, and this means that the epidermis may not have been fully 
restored. miR-191 might have affected the wound healing by increasing the cellular senescence, 
meaning that the diploid differentiation among an increased number of cells ceases (Campisi & 
d’Adda di Fagagna, 2007). If the differentiation of cells is decreased in the wound healing process, 
the damaged tissues might not be fully restored.      
It is also suggested that miR-191 is an important factor in differentiation and development of cells, 
by targeting many proteins relevant to cell proliferation, differentiation and migration among others. 
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(reviewed by Nagpal & Kulshreshtha, 2014). Therefore, the increase of the relative expression of 
miR-191 in the wt STZ mice could have decreased the differentiation and development of the cells 
that participate in the wound healing phases.  
In wt STZ mice compared to wt mice, day 0, miR-191 was highly increased on day 0, but on day 3 
and day 10 the fold changes were only 1.2. 
Therefore, the miR-191 may not have had an increased effect on cellular senescence and a 
decreased effect on proliferation of keratinocytes after 3 and 10 days in wt STZ mice. Hereby, 
presuming that miR-191 was only increased on day 0, and that the relative expression of miR-191 
was not increased on any of the following days, the miRNA might only have had a negative impact 
on the wound healing process on the first day or just the first few hours. This would need further 
research to be validated, and is therefore only a conjecture so far.    
 
miR-574-3p 
Over-expression of mir-574-3p has been shown to target and cause reduction in the rate of cell 
growth in A549 cells and to suppress the production of Enhancer of Rudimentary Homolog (ERH) 
proteins (Ishikawa et al., 2014). The cells used in Ishikawa et al. (2014) experiment are lung 
adenocarcinoma, A549 cell line. The lung epithelial cells may not function as the epithelial cells in 
the skin, and they might therefore not have any effect on the wound healing in skin. However, the 
predicted target ERH protein is expressed in most eukaryotes cells where it has several functions, 
such as regulating transcription, cell cycle and mRNA splicing (Weng & Luo, 2013). 
The exact time that the skin samples were extracted from the mice is unknown, thus it is not 
possible to know when the miRNAs have an impact on the wound healing process. The hemostatic 
phase initiates quickly after injury and is overlapped by the inflammatory phase. Whereas, the 
proliferative phase and the remodeling phase initiate days after the injury. It can be postulated that 
the hemostatic phase and the inflammatory phase initiate during day 0 and the remaining two 
phases initiate during day 3 and day 10.  Although it has been showed that angiogenesis is initiated 
shortly after injury. Therefore, certain proteins from the angiogenesis process could occur on day 0.   
The results of the experiment executed in this report showed that there was a relative decreased 
expression of miR-574-3p, in the wt STZ mice on day 3 by a fold change of 0.4 and on day 10, by a 
fold change of 0.23, compared to wt mice day 0. In the wt mice, the miR-574-3p was decreased by 
0.88 fold change on day 3 and by 0.39 fold change on day 10. This could indicate that the 
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production of the ERH proteins was not suppressed. This experiment also showed that on day 0, 
miR-574-3p relatively increased in the wt STZ mice with a fold change of 3.88 compared to the wt 
mice on day 0. Since miR-574-3p was only up-regulated on day 0, it seems likely that the wound 
healing processes that generally takes place during the very first phases of wound healing was 
effected.  
This increase could affect the hemostatic phase and the inflammatory phase in wound healing by a 
slower rate of cell growth, thus leading to an impaired wound healing. Because the ERH protein is 
expressed in most eukaryote cells, it is not known which effect miR-574-3p’s down-regulation of 
the ERH protein would have specifically on wound healing. It could possibly effect platelets or 
other components in the blood clot, during the first phase. Because of a possible slower cell growth 
of the cells involved in the blood clot, the bleeding may not be prevented as efficiently and neither 
will there be created a temporary protective barrier. It might also affect the inflammatory phase, by 
slowing the growth rate of some leukocytes and thereby preventing an efficient protection against 
pathogens and the degradation and formation of tissue. 
It has also been shown that miR-574-3p targets the CULLIN2 (CUL2) protein. This protein is 
required for vasculogenesis to take place. The CUL2 protein is located in the cytoplasm, and is 
involved in cell cycle regulation and is incorporated in a polypeptide, which functions as a protein 
degradation. The CUL2 protein being an element in the complex called ElonginB/C-CUL2-RBX-1-
Von Hippel-Lindau (VHL) tumor suppressor complex, functions as a protein degradation (Maeda et 
al., 2008; Su et al., 2012). 
This particular VHL complex degrades hypoxia-inducible factor α (HIF-α), which functions as a 
mediate for the expression of VEGF (Maeda et al., 2008). VEGF is a growth factor, which is 
important in angiogenesis in the proliferative phase during wound healing by stimulating the 
migration of endothelial cells. This phase occurs during day 3 and day 10 after the injury. The 
miRNA was down-regulated on both day 3 and day 10 in wt STZ mice, which could indicate that 
miR-574-3p increased the relatively amount of the VHL complex because the CUL2 protein 
inhibition was reduced. Thus, the degradation of HIF- α could be increased, leading to a possibly 
increased expression of VEGF. This could increases the rate of the endothelial cells migration and 
therefore have a positive effect on wound healing in the wt STZ mice. The VEGF protein is not 
involved in the earlier phases of the wound healing process, and it should therefore not affect the 
wound healing process that miR-574-3p was increased on day 0 in the w STZ mice.  
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Thereby it is shown in the experiment executed in this report that mir-574-3p could indeed have a 
degrading impact on cell growth. During the two first phases of the wound healing process, there 
was an increased expression of miR-574-3p in wt STZ mice on day 0, compared to wt mice on day 
0. Thus, it can be speculated that miR-574-3p could cause slow and insufficient wound healing 
among wt STZ mice because of the predicted target ERH protein was down-regulated on day 0. 
However, miR-574-3p might also have had a positive effect on the angiogenesis process, by 
indirectly effecting the amount of the VEGF protein.  
 
miR-193b 
miR-193b has been shown to target Smad3, which is a promoting regulator of glioma cell growth 
and proliferation through a TGF-β pathway. Glioma is type of brain tumor (Zhong et al., 2014). An 
up-regulation of miR-193b, decreases the expression of Smad3, and thus results in a down-
regulation of glioma cell growth and proliferation. It can be speculated that an up-regulation of 
miR-193b could have an impact on cell growth and proliferation in skin cells, due to its targeting of 
Smad3. Cell proliferation is important in the proliferative phase of wound healing, where 
keratinocytes, fibroblasts and endothelial cells proliferate. The results of this study showed a little 
up-regulation of miR-193b by a 1.3 fold change on day 3 of wt mice compared to day 0, and a little 
down-regulation by a 0.8 fold change on day 10. This might indicate that expression of Smad 3 is 
reduced on day 3 in wt mice and increased on day 10, which could result in increased cell 
proliferation of keratinocytes, fibroblasts and endothelial cells on day 10 in the proliferative phase. 
According to the theory the proliferative phase starts within 24 hours of injury, and therefore miR-
193b was expected to be down-regulated on day 3 in wt mice. When comparing the wt STZ mice 
with the wt mice on day 0, there was an up-regulation by a 6.1 fold change on day 0, and a down-
regulation on day 3 and 10 by a 0.7 and 0.6 fold change, respectively. miR-193b was down-
regulated more in wt STZ mice compared to wt mice day 0 than in wt mice on day 3 and day 10, 
which might indicate that proliferation off cells is enhanced in wt SZT mice. The high up-regulation 
of miR-193b in wt STZ mice on day 0 might affect the wound healing process, but since Smad3 
effects cell proliferation, which does not occur on day 0, it is unknown which effect it might have 
on day 0 and therefore more research are required. 
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miR-133a 
It has been showed that miR-133a is down-regulated in breast cancer cells and tissue. A possible 
target for miR-133a is epidermal growth factor receptor (EGFR), which is involved in cell 
proliferation. There was an increased cell proliferation in breast cancer cells when miR-133a was 
down-regulated (Cui et al., 2011). It can be speculated that a down-regulation of miR-133a could 
increase cell proliferation in skin cells, due to its targeting of EGFR. In wound healing there is as 
mentioned cell proliferation of keratinocytes, fibroblasts and endothelial cells in the proliferative 
phase, which starts 24 hours after injury and continues for weeks. The results of this experiment 
showed an up-regulation of miR-133a in wt mice on day 3 by a 2.4 fold change compared to day 0, 
which might indicated that cell proliferation was decreased, but according to our expectations which 
are based on the written theory on wound healing in this report, cell proliferation should be 
increased on day 3 and day 10. miR-133a was down-regulated by a 0.8 fold change on day 10 of wt 
mice compared to day 0, as expected. When comparing the wt STZ mice with wt mice on day 0, 
there was an up-regulation on day 0 and day 3 by a 9.3 and 2.1 fold change, respectively. This 
might indicate that the proliferation was more decreased in wt STZ mice on day 3, which could be a 
reason for ulcer formation in wt STZ mice. On day 10 there was a down-regulation by a 0.5 fold 
change of the wt STZ mice compared to the wt mice on day 0, thus the proliferation could be 
increased among wt STZ mice on day 10. So the results did not fully agree with the breast cancer 
study, this could be caused by other miRNAs that increases or decreases the proliferation. The high 
relative expression of miR-133a on day 0 of wt STZ mice compared to day 0 of wt mice, might 
have an influence on the wound healing process, but it would require further research to confirm.   
 
miR-126-3p 
It is shown that miR-126-3p influences the epithelial cells in mouse mammary, by decreasing 
proliferation of mammary epithelial cells (Cui et al., 2011). Though it is shown in epithelial cells in 
mouse mammary, it could be speculated that miR-126-3p could be expressed in epithelial cells in 
mammalian skin in general. The insulin receptor substrate-1 (IRS-1), which is involved in cell 
growth, is a predicted target of miR-126-3p (Zhang et al., 2008). It has been shown that miR-126-3p 
down-regulates IRS-1 (Zhang et al., 2008). Another predicted target of miR-126-3p is the PGR 
protein (Cu et al., 2011), which has been shown to be positively involved with endothelial cell 
proliferation and in regulation of vascular systems (Vazquez et al. 1999). Thus miR-126-3p could 
be an important participant in the process of wound healing and skin development, due to its down-
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regulating effect on epithelial and endothelial cells and cell growth in the vascular systems. Seeing 
as epithelial cells, endothelial cells and the vascular system play an important role in wound 
healing, an up-regulation of miR-126-3p, if up-regulated in wt STZ mice, could be one of many 
causes to deficient wound healing and skin development.  
In wt mice, miR-126-3p was up-regulated by 50 % on day 3 and by 20 % on day 10, compared to 
wt mice day 0. When comparing wt STZ mice day 0, 3 and 10 to wt mice day 0, there was a high 
up-regulation on day 0 in wt STZ mice by 200 %, but then a rather steady down-regulation of miR-
126-3p from day 0-3 by 100 %, and from day 3-10 by 28 %, in wt STZ mice. Seeing as miR-126-3p 
was highly up-regulated on day 0 in wt STZ mice, compared to wt mice on day 0, it would seem 
that miR-126-3p’s negative regulation of epithelial cells, would be quite active on the first day of 
the wound impact. This could potentially slow down the healing process seeing as the proliferation 
of epithelial cells are quite important for the initiation of the healing process. However, miR-126-3p 
appeared to be down-regulated in wt STZ mice on day 3 by 65 % and further by 11 % on day 10. 
However, miR-126-3p’s down-regulation on day 3 and day 10 in wt STZ mice could imply that 
miR-126-3p’s negative impact on epithelial cells was lowered notably and thus miR-126-3p’s 
negative impact on the wound healing process might be limited. Further research is needed in order 
to validate these speculations. 
 
miR-150 
A predicted target of miR-150 is the BAK1 protein, which is known to induce cell apoptosis in non-
small-cell lung cancer (NSCLC) (Shi et al., 2007; Gu et al., 2014). A decrease of miR-150 was 
shown to cause cell cycle arrest during the cell cycle phase G0/G1 in NSCLC through the targeting 
of the BAK1 protein (Gu et al., 2014). If the BAK1 protein can induce cell apoptosis in NSCLC it 
can be speculated that the BAK1 protein might induce cell apoptosis in cells in general, and thus in 
the skin. If this were to be true then the fact that the BAK1 protein is a predicted target of miR-150, 
could mean that an up- or down-regulation of miR-150 would affect the wound healing process. But 
this is speculations and would need further research to be validated. 
miR-150 was up-regulated by 226 % on day 3 in wt STZ mice. miR-150 who’s presence increases 
cell proliferation and decreases apoptosis, might have had a positive regulation on wound healing in 
wt STZ mice due to its high up-regulation on day 3. But on day 10 a heavy down-regulation took 
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place in wt STZ mice by 218 %, from day 3 to day 10. This implies that miR-150’s positive effect 
on cell proliferation and negative effect on apoptosis, could have worn off in between day 3 and day 
10 in wt STZ mice. 
When comparing wt STZ mice day 0, 3 and 10 to wt mice day 0, no notable regulation occurred 
until day 3 where mir-150 was up-regulated by 313% in wt STZ mice. On day 10 miR-150 was 
heavily down-regulated; on day 3 in wt STZ mice compared to wt mice day 0, there was a fold 
change of 4, but on day 10 in wt STZ mice compared to wt mice day 0, the fold change was only 
0,5. This could all indicate that the wound healing process would have been positively regulated by 
miR-150 when up-regulated, but could have been impaired due to the insufficiency of miR-150, 
from somewhere between day 3 and day 10. 
 
miR-342-3p 
miR-342-3p is known to be related to many important cell processes such as; cell differentiation, 
migration and proliferation (Zhao et al., 2012). A predicted target of miR-342-3p is the growth 
factor TGF-β (Zhao et al., 2012). TGF-β is thought to be secreted by macrophages in the 
inflammatory phase around 2 days after wound impact. Once secreted, TGF-β stimulates the cell 
proliferation in the proliferative phase. This indicates that miR-342-3p, if up-regulated, could be a 
negative regulator of wound healing, due to the impact that TGF-β has on cell proliferation and 
miR-342-3p could thereby impair the wound healing process. TGF-β is not the only protein that 
stimulates cell proliferation and therefore it is difficult to predict the influence that TGF-β might 
have on the wound healing process. 
miR-342-3p was highly down-regulated on day 3 and day 10, in wt STZ mice by 85 % and 70 % 
respectively. When comparing wt STZ mice day 0, 3 and 10 to wt mice on day 0, the most notable 
regulation was found on day 0 by 214 % in the wt STZ mice. On day 3 in the wt STZ mice miR-
342-3p was down-regulated by 52 % compared to wt mice day 0, and only by 4 % on day 10, also 
compared to day 0 wt mice. This might indicate that miR-342-3p in wt STZ mice on day 0 had a 
negative regulation on wound healing, indicating that if miR-342-3p had any noteworthy effect on 
wound healing, it would only have been in the initiating phase of wound healing. However, seeing 
as miR-342-3p’s predicted target TGF-β isn’t secreted by macrophages until day 2, it could be 
speculated that miR-342-3p doesn’t negatively effect the wound healing process, if miR-342-3p 
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was down-regulated before TGF-β was considerably present. Whether or not miR-342-3p could 
notably cause a slower wound healing process would need further research and further knowledge 
about other skin related targets of miR-342-3p.  
 
miR-1937b and miR-1937c 
Due to mir-1937b and mir-1937c not being actual miRNAs but tRNAs and due to the late discovery 
of the two, there is very little research done concerning these two tRNAs, in context to miRNA. 
Therefore it has not been possible to find relevant research on tRNA 1937b and 1937c for this 
project. 
 
5.2 INTERESTING MIRNAS 
In earlier studies it has been demonstrated that different miRNAs have influence on skin 
proliferation and wound healing (van Solingen et al., 2014). Some of these miRNAs and their 
function will be described here. They are selected on the basis of their influence on wound healing. 
Afterwards the procedure, used for selecting the then miRNAs, was followed. Ct values and fold 
changes were used (Appendix D, Table 7.10). 
 
miR-155 
A decrease of the expression of miR-155, possibly due to targeting the transcription factor C/EBP-β 
(Hebenstreit et al., 2006), can lead to an increase of expression of the inflammatory zone-1 (FIZZ1) 
gene (van Solingen et al., 2014) which stimulates myofibroblast differentiation (Liu et al., 2004) 
and thereby the production of smooth muscle cells. The results of the experiment executed in this 
report showed that miR-155 was weakly decreased on day 3 by a 0.8 fold change and increased on 
day 10 by a 2.32 fold change compared to day 0 of the wt mice. The inflammatory phase in wound 
healing runs from the first couple of hours after the wound is made to a couple of days. miR-155 
was less present on day 0 and day 10 in the wt mice and thereby FIZZ1 gene could possibly be up-
regulated and assist in the wound healing. miR-155 was very up-regulated on day 3 and 10 in the wt 
STZ mice compared to the wt STZ mice day 0 by a 13.2 and 11.7 fold change, respectively 
(Appendix D, Table 7.11). When the wt STZ mice, day 0, 3 and 10, were compared to the wt mice, 
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day 0, the relative expression of miR-155 was down-regulated on day 0 by a 0.06 fold change and 
by a 0.8 and a 0.7 fold change on day 3 and 10, respectively (Appendix D, Fig. 7.1, Table 7.12). 
This means that the wound healing was possibly stimulated by the decrease of miR-155 and thereby 
the increase of the expression of the FIZZ1 gene. If miR-155 actually targeted one of the three 
mentioned proteins BCL6, RhoA and SHIP1 and thereby had an influence on the FIZZ1 gene, the 
wound healing in the wt STZ mice would not be impaired but stimulated, which was not expected. 
 
miR-200b 
Down-regulation of the miR-99 family (miRNA-99a, miRNA-99b, miRNA-100) in keratinocytes 
(Jin et al., 2013) supports wound closure (van Solingen et al., 2014) by regulating cell proliferation 
and cell migration (Jin et al., 2013). Furthermore a decrease of miR-99a-5p and miR-200b 
stimulates the wound healing process by increasing the cutaneous wound angiogenesis (Chan et al., 
2012
b
) due to targeting the transcription factor, Ets-1 (Chan et al., 2011). The results of the miR-99 
family, in this report, are chosen not to be used because the Ct values either were too high or the 
data for the wt STZ mice were undetermined. This means that these miRNAs were not expressed at 
all or were inconclusive. If the miRNAs were not expressed it would mean that the wound healing 
in the wt STZ mice was stimulated. miR-200b was not notably down-regulated, less than 10 %, on 
day 3 compared to day 0 in the wt mice. On day 10, miR-200b was up-regulated by almost 50 % in 
the wt mice. In the wt STZ mice miR-155 was down-regulated by almost 40 % on day 3 and up-
regulated by approximately 30 % on day 10 compared to day 0 in the wt STZ mice (Appendix D, 
Table 7.11). In general, the results of miR-200b in the wt STZ mice were decreased, day 0 by less 
than 40 %, day 3 approximately by 60 % and day 10 only by 20 % compared to the wt mice on day 
0 (Appendix D, Fig. 7.2, Table 7.12). This could indicate that the wound healing was stimulated in 
the wt STZ mice more than in the wt mice. If it was assumed that the apparently stimulated wound 
healing in the wt STZ mice was due to down-regulation of miR-200b, the wound healing process 
did proceed in optimum manner because angiogenesis is present in the proliferative phase, which 
starts of after 24 hours and the results showed a down-regulation on day 3 and an up-regulation on 
day 10. 
 
 
Page 47 of 69 
 
miR-210 
Decrease of miR-210 in keratinocytes up-regulates cell proliferation in regards to wound healing 
(Biswas et al., 2010) by targeting proteins important to cell cycle, for example the transcription 
factor E2F3 (Chan et al., 2012
a
). The results of miR-210, in this experiment, showed that there was 
an up-regulation on day 3 and 10 compared to day 0 in the wt mice by a 2.03 and 3 fold change, 
respectively. miR-210, in the wt STZ mice, was up-regulated on day 3 by almost a half fold change, 
compared to day 0 while day 10 had a fold change almost equal to the fold change on day 0 
(Appendix D, Table 7.11). For the comparison of the two types of mice, the wt STZ mice were only 
up-regulated by nearly 10 % on day 0 and 10, where day 3 was up-regulated by 50 % (Appendix D, 
Fig. 7.3, Table 7.12). This suggests that the wound healing was decreased in the wt STZ mice 
compared to the wt mice day 0 due to miR-210 being down-regulative of cell proliferation. If miR-
210 actually targeted E2F3 in this experiment, cell proliferation, which starts of 24 hours after the 
wound is made, would be inhibited on day 3, especially. 
 
miR-203 
miR-203, in skin morphogenesis, directly regulates the expression of the p63 gene. Thereby a 
down-regulation of miR-203 leads to an up-regulation of expression of the p63 gene (Yi et al., 
2008). p63 promotes proliferation of epidermis (Koster et al., 2004). miR-203, in the wt mice, was 
down-regulated by a 0.85 fold change on day 3 compared to day 0. It was then up-regulated by a 2.2 
fold change on day 10 compared to day 0. On the other hand miR-203, in the wt STZ mice, was up-
regulated by a 2 fold change on day 3 and down-regulated by a 0.8 fold change on day 10 compared 
to day 0 (Appendix D, Table 7.11). Finally, when the wt STZ mice were compared to the wt mice 
on day 0, there was an up-regulation of miR-203 by a 1.5 fold change on day 3 and a down-
regulation by a 0.7 and 0.6 fold change on day 0 and 10 in the wt STZ mice, respectively (Appendix 
D, Fig. 7.4, Table 7.12). Thus, the proliferation of epidermis could be reduced on day 3 in the wt 
STZ mice compared to the wt mice day 0 if miR-203 targeted the mRNA of the p63 gene. Hereby 
the wound healing could possibly be impaired in the wt STZ mice because the proliferation phase is 
supposed to initiate within 24 hours after the wound is made, and this was not the case. 
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miR-205 
miR-200 and miR-205 are predicted to target ZEB1 and ZEB2, which have an inhibiting effect on 
E-cadherin. E-cadherin assists in the maintenance of epithelial stability. An increase of miR-200 
and miR-205 leads to an increase of E-cadherin, resulting in improved wound healing (reviewed by 
Banerjee et al., 2011). miR-205 was both up-regulated on day 3 and day 10 by a 1.3 and 1.75 fold 
change, respectively, in the wt mice. In the wt STZ mice it was also up-regulated, but a little less, 
by a fold change of 1.2 on day 3 and a fold change of 1.24 on day 10 compared to the wt STZ mice 
day 0 (Appendix D, Table 7.11). When the wt STZ mice were compared to the wt mice, day 0, the 
expression of miR-205 was down-regulated by a 0.71 fold change on day 0, a 0.84 fold change on 
day 3 and a 0.88 fold change on day 10 (Appendix D, Fig. 7.5, Table 7.12). This could mean that E-
cadherin was inhibited and so could the maintenance of the epithelial stability of the wt STZ mice 
be compared to the wt mice on day 0. It would need further studies to validate if miR-205 targeted 
ZEB1 and ZEB2 and thereby affected the wound healing process through epithelial stability. 
 
miR-92a 
miR-92a, due to targeting the a5 integrin subunit (TGA5), is down-regulative of angiogenesis 
(Bonauer et al., 2009). Thus, a down-regulation of miR-92a up-regulates angiogenesis and thereby 
increases wound healing. miR-92a was up-regulated by a 1.8 fold change in wt mice on day 3 
compared to day 0 of the wt mice. On day 10, miR-92a was up-regulated by a 2.2 fold change 
compared to day 0. In the wt STZ mice, miR-92a was up-regulated by a fold change of 50 and 36 
on day 3 and 10 respectively, compared to day 0 (Appendix D, Table 7.11). When the wt STZ mice 
were compared to the wt mice on day 0, the expression of miR-92a was down-regulated on day 0 
and day 10 by a fold change of 0.02 and 0.88, respectively. The expression of miR-92a was up-
regulated on day 3 by a 1.24 fold change (Appendix D, Fig. 7.6, Table 7.12). Assuming that miR-
92a targeted TGA5 in the experiment executed in this report, the wound healing could probably be 
impaired on day 3. Since miR-92a only was up-regulated on day 3, the angiogenesis could possibly 
be down-regulated on day 3 but not on day 0 or day 10, where miR-92a was down-regulated. It 
could be speculated that a lot of other miRNAs influence angiogenesis in the wt STZ mice 
compared to the wt mice day 0 by up- or down-regulating angiogenesis. Thereby angiogenesis 
could, for example, be down-regulated throughout all three days, which could be expected for the 
wt STZ mice, due to the knowledge of impaired wound healing among diabetic patients. But 
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nothing can be concluded when only looking at miR-92a because other miRNAs, influencing 
angiogenesis, need to be examined. Thus, more studies are needed to determine what happens 
overall. 
The results of the experiment executed in this report, shows which miRNA are up-regulated and 
down-regulated in wt STZ mice compared to wt mice during wound healing. It still need further 
research for a conclusive answer of how this up-regulation or down-regulation effect the wound 
healing. This could be done by first researching the specific miRNA’s targets, and thereafter how 
these targets affect the wound healing. 
 
5.3 GLUCOSE-REGULATED MIRNAS 
It has been shown that many miRNAs are regulated by the glucose concentration. In MIN6 cells, 
located in β-cells in pancreas, miR-124a, miR-107 and miR-30d are up-regulated by high glucose 
concentrations. Whereas a high glucose level significantly down-regulates miR-296, miR-484, miR-
612, miR-638, miR-663 and miR-690. The miRNAs in MIN6 cells, regulated by a high glucose 
level, might have a big influence on insulin production and secretion (Tang et al., 2009).  
miR-29a is down-regulated by a high glucose level, which results in an increase of collagen IV 
production in HK-2 cells (Du et al., 2010). miR-32-5p is down-regulated by a high glucose level in 
stem cells derived from the bone marrow and results in decreased cell cycle progression (Zhu et al., 
2013). A high glucose level up-regulates miR-221 in human umbilical vein endothelial cells, and 
results in reduced cell migration of endothelial cells (Li et al., 2009). miR-1 and miR-206 are up-
regulated by a high glucose level in myocardium, which is muscular tissue in the heart. Up-
regulation of miR-1 and miR-206 may increase apoptosis in cardiomyocytes, also known as muscle 
cells (Shan et al., 2010). The result of this report does not fully correspond to this research. The wt 
STZ mice have diabetes and thereby a high level of glucose in their blood. Therefore wt STZ mice 
were compared to wt mice day 0, to see if the same miRNAs were up- and down-regulated by a 
high level of glucose (Appendix D, Table 7.12). miR-124, miR-107, miR-30d, miR-221, miR-1 and 
miR-206 were shown to be up-regulated in present studies. The results of this report show that miR-
30d was up-regulated on day 0 in the wt STZ mice compared to wt mice day 0. The rest of the 
miRNAs were either down-regulated or undetermined. Present studies show that miR-296, miR-
484, miR-612, miR-638, miR-663, miR-690, miR-629a and miR-32-5p were down-regulated in 
presence of high level of glucose. The result of this project showed that miR-484 was down-
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regulated on day 0 and 10, and that miR-629a was down-regulated on day 3 and 10 and at last that 
miR-690 was down-regulated on all days of wt STZ mice compared to wt mice day 0. The rest of 
the miRNAs that were expected to be down-regulated were up-regulated, undetermined or not 
present in the Array. Some of the miRNAs in wound healing might also be regulated by glucose, 
but more research is necessary. 
 
5.4 LIMITATIONS OF THE STUDY 
The wt STZ mice, had received a daily i.p. injection of 50 mg/kg STZ in 200 µl citrate buffer with 
pH 4.2 for 5 days, and in that way the mice develop diabetes. STZ is poison for the beta-cells and 
therefore they are destroyed. Because the beta-cells are destroyed completely or partly, the mice are 
most likely to have type 1 diabetes. Therefore this experiment shows which miRNAs are up- or 
down-regulated in wound healing among type 1 diabetic mice. If miRNAs should be used as a 
treatment for wound healing among diabetic patients, more studies are necessary. Both experiments 
with type 1 and type 2 diabetes are important, to see if the same miRNAs are up- or down-regulated 
in wound healing among type 1 and type 2 diabetic mice. Furthermore it should be examined if the 
same miRNAs are up or down-regulated in wound healing among humans compared to mice, 
because they have different physiologies.    
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Wound healing is divided into four overlapping phases, which include the hemostatic phase, the 
inflammatory phase, the proliferative phase and the remodeling phase. 
Ten miRNAs were selected on the basis of their Ct values and their fold changes. All of the ten 
selected miRNAs could possibly have had an impaired effect on wound healing when wt STZ mice 
were compared to wt mice day 0. 
The expression of miR-191 was up-regulated on all three days, and if targeting CDK6 and SATB1 
this could cause an increase of cell senescence and a decrease of proliferation in keratinocytes and 
differentiation and development of cells and thereby impair wound healing. 
The expression of miR-133-a was up-regulated on two out of the three days, and if targeting EGFR 
this could cause a decrease of cell proliferation, which inhibits wound healing. 
Six of the ten selected miRNAs could have had an impaired effect on wound healing on one out of 
the three days. Five of those were increased on one of the days, while one was decreased on one of 
the days, both possibly causing impaired wound healing. miR-320, miR-574-3p, miR-193b, 126-3p 
and 342-3p were increased, and if targeting their respective targets, VEGF and fibronectin, ERH, 
Smad3, PGR and IRS-1 and TGF-β, this could cause a decrease in cell proliferation, angiogenesis, 
cell migration, apoptosis inhibition, rate of cell growth and epithelial cells. miR-150 was decreased 
on one out of the three days, and if targeting its predicted target, BAK1, it could cause an up-
regulation of cell apoptosis. In both cases wound healing could be inhibited. Due to the late 
discovery of mir-1937b and mir-1937c it has not been possible to examine their predicted targets. 
Furthermore some miRNAs, miR-155, miR-200b, miR-210, miR-203, miR-205 and miR-92a, were 
selected on basis of their importance in wound healing according to present research. These six 
miRNAs were compared to the results of the experiment executed in this report. The theory says 
that wound healing among diabetic patients is impaired compared to non-diabetic patients. On this 
basis it was expected that some of the selected miRNA would be up- or down-regulated in regards 
to impaired wound healing. This was the case for some of the miRNAs but not for others. This can 
be explained through miRNAs multiple targeting and their versatile targets. This means, even 
though a miRNA is up-regulated, it does not necessarily target the specific protein that assists in 
wound repair. Additionally an up-regulated miRNA might have a suppressing effect on a target that 
has an impaired effect on wound healing. 
6. CONCLUSION 
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Four of the six interesting miRNAs could possibly have had an impaired effect on wound healing 
when wt STZ mice were compared to wt mice day 0. 
miR-210 and miR-205 were increased or decreased on all of the three days, respectively, and if 
targeting their respective targets, E2F3 and ZEB1 and ZEB2, this could cause a decrease in cell 
proliferation and maintenance of epithelial stability, which would inhibit wound healing. 
miR-203 and miR-92a were up-regulated on one out of the three days, and if targeting their 
respective targets, p63 and TGA5, this could cause a down-regulation of proliferation of epidermis 
and angiogenesis and thereby impair wound healing. 
miR-155 and miR-200b were decreased on all three days and if targeting their respective targets, 
C/EBP-β and Ets-1, this would cause an increase of myofibroblast differentiation and cutaneous 
wound angiogenesis, which would improve wound healing. 
The majority of the examined miRNAs appeared to potentially have an impaired effect on wound 
healing, but in order to validate these assumptions further research is needed.    
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Table 7.1 The RNA concentrations, the ratios, the yields of all the mice skin samples were measured on the 
Nanodrop1000. 
# Condition Days post-wounding Conc. (ng/uL) Volume (uL) Ratio Yield (ug) 
1 WT Day 0 (baseline) 741 40   29,64 
2 WT Day 0 (baseline) 419 40 1,94 16,76 
3 WT Day 0 (baseline) 580 40 1,96 23,20 
4 WT Day 0 (baseline) 1253 40 2,01 50,14 
5 WT Day 0 (baseline) 1251 25 2,03 31,27 
6 WT Day 0 (baseline) 1381 25 2,04 34,52 
1 WT Day 3 1241 40 2 49,64 
2 WT Day 3 704 40 1,96 28,16 
3 WT Day 3 817 40 1,99 32,68 
4 WT Day 3 1076 40 2,02 43,02 
5 WT Day 3 1367 40 2,01 54,66 
6 WT Day 3 1245 40 2,04 49,80 
1 WT Day 10 111 40 1,81 4,44 
2 WT Day 10 708 40 2,01 28,32 
3 WT Day 10 718 40 2,02 28,72 
4 WT Day 10 1507 40 2,03 60,28 
5 WT Day 10 1721 40 2,02 68,85 
6 WT Day 10 1700 25 2,03 42,50 
1 WT STZ Day 0 (baseline) 403 40 1,91 16,12 
2 WT STZ Day 0 (baseline) 654 40 2 26,16 
3 WT STZ Day 0 (baseline) 249 40 1,95 9,96 
4 WT STZ Day 0 (baseline) 671 25 2,02 16,77 
5 WT STZ Day 0 (baseline) 2619 25 2,04 65,48 
6 WT STZ Day 0 (baseline) 896 25 2 22,40 
1 WT STZ Day 3 429 40 1,94 17,16 
2 WT STZ Day 3 531 40 1,96 21,24 
3 WT STZ Day 3 353 40 1,89 14,12 
4 WT STZ Day 3 632 40 1,97 25,30 
5 WT STZ Day 3 720 40 1,99 28,81 
6 WT STZ Day 3 991 40 1,99 39,64 
1 WT STZ Day 10 618 40 1,96 24,72 
2 WT STZ Day 10 868 40 1,98 34,72 
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3 WT STZ Day 10 798 40 1,98 31,92 
4 WT STZ Day 10 3187 25 2,03 79,67 
5 WT STZ Day 10 2008 40 2,04 80,33 
6 WT STZ Day 10 1908 25 2,05 47,71 
 
Table 7.2 The Ct values of the ten different miRNAs on day 0, day 3 and day 10 for wt and wt STZ 
mice, respectively.   
Target 
Name 
ct wt day 
0 
ct wt day 
3 
ct wt day 
10 
ct wt STZ day 
0 
ct wt STZ day 
3 
ct wt  STZ day 
10 
miR-126-
3p 
23,859 23,27 23,11 25,389 23,096 23,6060009 
miR-133a 22,983 21,733 22,932 22,907 21,233 23,3029995 
miR-191 23,372 22,597 22,312 24,536 22,466 22,37999916 
miR-193b 26,316 25,953 26,097 26,851 26,188 26,24399948 
miR-320 25,451 25,089 24,161 26,102 25,12 25,31800079 
miR-342-
3p 
28,497 28,44 27,226 29,99 28,858 27,81699944 
miR-574-
3p 
26,635 26,831 27,497 27,824 27,217 28,00300026 
miR-150 27,795 27,634 27,427 30,597 25,075 27,87999916 
miR-1937c 17,129 17,466 16,503 24,476 16,346 17,032 
miR-1937b 14,889 15,251 14,414 19,773 13,930 14,592 
 
Table 7.3 The geometric means of the reference gene U6 on all six days. 
Day  Geometric mean 
0 wt 17,62558733 
3 wt 17,90761599 
10 wt 17,34482845 
0 wt STZ 20,33400669 
3 wt STZ 16,89108405 
10 wt STZ 17,18999286  
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Table 7.4 The calculated fold changes of the wt mice on day 0, day 3 and day 10.   
Target Name 2^-(ΔΔct) 
d 0 
2^-(ΔΔct) d 
3 
2^-(ΔΔct) d 
10 
miR-126-3p 1 1,519161453 1,216716237 
miR-133a 1 2,40206703 0,750016737 
miR-191 1 1,728206998 1,509419237 
miR-193b 1 1,298888219 0,842643303 
miR-320 1 1,297986989 1,770301413 
miR-342-3p 1 1,050645243 1,747138536 
miR-574-3p 1 0,881649582 0,398318554 
miR-150 1 1,129180178 0,934323546 
miR-1937c 1 0,962613637 1,270362799 
miR-1937b 1 0,946076136 1,144122479 
 
Table 7.5 The calculated fold changes of the wt STZ mice on day 0, day 3 and day 10.  
Target Name 2^-(ΔΔct) STZ  
day 0 
2^-(ΔΔct) STZ  
day 3 
2^-(ΔΔct) STZ  
day 10 
miR-126-3p 1 0,348221867 0,235402626 
miR-133a 1 0,226735033 0,051983709 
miR-191 1 0,2983503 0,304856755 
miR-193b 1 0,112506444 0,104183855 
miR-320 1 0,140347754 0,117782881 
miR-342-3p 1 0,155725748 0,308470326 
miR-574-3p 1 0,108223056 0,060421358 
miR-150 1 3,264990512 0,449752823 
miR-1937c 1 25,7602827 19,69812512 
miR-1937b 1 5,278316176 4,103875259 
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Table 7.6 The calculated fold change ratio between the wt mice and the wt STZ mice on day 0, day 
3 and day 10.   
Target Name 2^-(ΔΔct) STZ  
day 0 (wt) 
2^-(ΔΔct) STZ  
day 3 (wt) 
2^-(ΔΔct) STZ  
day 10 (wt) 
miR-126-3p 3,061485082 1,066076052 0,720681628 
miR-133a 9,319370796 2,113027847 0,484455456 
miR-191 3,945567394 1,177161217 1,202832871 
miR-193b 6,101789847 0,68649068 0,635707989 
miR-320 5,63038381 0,790211723 0,663162825 
miR-342-3p 3,141018215 0,489137412 0,968910911 
miR-574-3p 3,877785933 0,419665844 0,234301093 
miR-150 1,267716626 4,139082755 0,570159131 
miR-1937c 0,040146534 2,058610655 0,790811443 
miR-1937b 0,221352655 51,90030587 0,908403684 
 
 
Table 7.7 The fold changes of 36 miRNAs, which had Ct values below 30 all three days in the two 
types of mice and were common to all the days. The selected miRNAs are marked.  
miRNAs common to all days: 
2^-(ΔΔct) STZ  
day 0 (wt) 
2^-(ΔΔct) STZ  
day 3 (wt) 
2^-(ΔΔct) STZ  
day 10 (wt) 
let-7c 1,442161885 0,504634867 0,540151313 
miR-16 1,203496154 0,714650959 0,542778501 
miR-19b 0,310407111 0,668181749 0,835919883 
miR-24 1,375763347 0,432062182 0,375122716 
miR-125a-5p 1,527564504 0,546885614 0,728720068 
miR-126-3p 3,061485082 1,066076052 0,720681628 
miR-133a 9,319370796 2,113027847 0,484455456 
miR-145 1,933522492 0,72663908 0,251989431 
miR-146a 1,901623159 0,402848987 0,507836083 
miR-146b 1,427245713 1,235685508 1,2154037 
miR-191 3,945567394 1,177161217 1,202832871 
miR-193b 6,101789847 0,68649068 0,635707989 
miR-199a-3p 1,312423597 0,633454463 0,617468013 
miR-200c 2,654117569 0,642741628 0,879913785 
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miR-203 0,732668212 1,535077334 0,596021266 
miR-214 2,038109777 0,891502619 0,829569636 
snoRNA202 0,625999168 1,048489272 0,545418466 
miR-222 0,338735939 0,710699346 0,466657203 
miR-223 0,672326204 2,207344036 0,435407027 
miR-320 5,63038381 0,790211723 0,663162825 
miR-342-3p 3,141018215 0,489137412 0,968910911 
miR-484 0,9177879 1,62710908 0,429114567 
miR-574-3p 3,877785933 0,419665844 0,234301093 
miR-652 5,768639912 1,195249064 0,432998901 
miR-29a 2,167801204 0,608492866 0,582946796 
miR-223 0,169860065 0,004702595 0,616172005 
miR-200c 0,485121677 0,0001374 0,536781047 
miR-200b 1,012848803 2,24E-05 0,951585933 
miR-720 0,454835933 0,005745596 1,20949484 
miR-2146 0,227733581 7,24E-05 0,653113929 
miR-2134 0,599743826 0,044184102 1,122258336 
miR-1274a 0,011059428 0,08488601 1,239197698 
miR-1951 0,240718809 0,000437227 1,462469654 
miR-1937c 0,040146534 2,058610655 0,790811443 
miR-1937b 0,221352655 51,90030587 0,908403684 
miR-206 0,43540154 9,17E-05 0,687487786 
 
Table 7.8 Some of the miRNAs were only common to wt mice, and some were only common to the 
wt STZ mice. The common miRNAs to each of the days are listed in the table below. 
 
 
miRNAs only common to day 0 wt 
miR-7a 
miR-190 
miR-204 
miR-329 
miR-741 
 
miRNAs only common to day 3 wt 0 
 
 
 
 
 
 
miR-10a 
miR-34a 
miR-103 
miR-130a 
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miRNAs only common to day 10 wt 
miR-196c 
miR-301a 
miR-376c 
miR-409-3p 
miR-431 
miR-434-3p 
miR-497 
let-7a 
miR-299-5p 
miR-203 
miR-409-3P 
miR-432 
miR-1957 
miR-1896 
miR-1897-5p 
miR-1894-3p 
miR-466g 
 
miRNAs only common to day 0  wt STZ miR-1193 
 
 
 
miRNAs only common to day 3 wt STZ 
miR-327 
miR-872 
miR-188-3p 
miR-99b 
miR-148b-5p 
 
miRNAs only common to day 10 wt STZ miR-743b-3p 
miR-34b-3p 
 
 
 
 
Table 7.9 Ct values of miR-1193 on all three days in the two types of mice.   
Target 
name 
ct wt day 0 ct wt day 3 ct wt day 
10 
ct wt stz 
day 0 
ct wt stz day 
3 
ct wt  stz day 
10 
miR-
1193 
Undetermined Undetermined 33,064 24,140 Undetermined Undetermined 
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Fig. 7.1 The bars shows the fold changes of miR-155 in wt mice, wt STZ mice and wt STZ mice 
compared to day 0 wt mice on all three days. 
 
 
Fig. 7.2 The bars shows the fold changes of miR-200b in wt mice, wt STZ mice and wt STZ mice 
compared to day 0 wt mice, on all three days. 
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Fig. 7.3 The bars shows the fold changes of miR-210 in wt mice, wt STZ mice and wt STZ mice 
compared to day 0 wt mice on all three days. 
 
 
Fig. 7.4 The bars shows the fold changes of miR-203 in wt mice, wt STZ mice and wt STZ mice 
compared to day 0 wt mice on all three days. 
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Fig. 7.5 The bars shows the fold changes of miR-205 in wt mice, wt STZ mice and wt STZ mice 
compared to day 0 wt mice on all three days. 
 
 
Fig. 7.6 The bars shows the fold changes of miR-92a in wt mice, wt STZ mice and wt STZ mice 
compared to day 0 wt mice on all three days. 
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Table 7.10 The Ct values of the interesting miRNAs on day all days.  
Target Name ct wt  
day 0 
ct wt  
day 3 
ct wt  
day 10 
ct wt 
stz  
day 0 
ct wt 
stz day 
3 
ct wt  
stz day 
10 
miR-155 27,61499977 27,95400047 25,93600082 34,761 27,222 27,343 
miR-200b 26,37999916 26,4829998 25,30400085 30,18 26,911 25,945 
miR-203 23,83399963 24,05500031 22,21299934 27,427 22,545 23,855 
miR-205 27,02099991 26,6760006 25,74099922 30,657 26,595 26,476 
miR-210 29,35400009 28,34499931 27,30599976 32,359 28,055 28,396 
miR-92a 28,224 27,402 26,595 36,719 27,235 27,669 
 
Table 7.11 Fold changes of the three different days with day 0 wt and day 0 STZ as control for the 
wt and wt STZ mice, respectively. 
Target Name 2^-
(ΔΔct)  
day 0 
2^-(ΔΔct)  
day 3 
 2^-(ΔΔct)  
day 10 
2^-(ΔΔct) 
STZ  
day 0 
2^-(ΔΔct) 
STZ  
day 3 
2^-(ΔΔct) 
STZ  
day 10 
miR-155 1 0,798450961 2,318180732 1 13,21478369 11,6981173 
miR-200b 1 0,940353933 1,526251175 1 0,684954683 1,288063654 
miR-203 1 0,866502453 2,226834577 1 2,095187575 0,813494098 
miR-205 1 1,282781741 1,758072769 1 1,186802371 1,2407419 
miR-210 1 2,032530763 2,993834427 1 1,40354984 1,066737002 
miR-92a 1 1,78543661 2,23921913 1 50,88189862 36,2574215 
  
Table 7.12 The fold changes of the wt STZ mice on day 0, day 3 and day 10 with day 0 wt as 
control. 
Target Name 2^-(ΔΔct) STZ  
day 0 (wt) 
2^-(ΔΔct) STZ  
day 3 (wt) 
2^-(ΔΔct) STZ  
day 10 (wt) 
miR-155 0,06242339 0,8249116 0,730236142 
miR-200b 0,634737153 0,434766186 0,817581856 
miR-203 0,732668212 1,535077334 0,596021266 
miR-205 0,711153382 0,843998521 0,882357798 
miR-210 1,101318131 1,545754887 1,174816801 
miR-92a 0,024505196 1,246870903 0,888495223 
 
 
 
Page 69 of 69 
 
Table 7.13 The calculated fold changes of wt STZ mice on day 0, 3 and 10 compared to wt mice 
day 0.  
 
Target Name 2^-(ΔΔct) STZ day 0 (wt) 2^-(ΔΔct) STZ day 3 (wt) 2^-(ΔΔct) STZ day 10 (wt) 
miR-124 0,412719301 0,412741634 0,634387331 
miR-107 #VÆRDI! #VÆRDI! #VÆRDI! 
miR-30d 1,207675284 0,613574905 0,546553911 
miR-221 #VÆRDI! 0,366353929 0,218913694 
miR-1 0,350924739 0,280352186 0,227894274 
miR-206 0,43540154 9,17249E-05 0,687487786 
miR-296-3p #VÆRDI! #VÆRDI! #VÆRDI! 
miR-296-5p #VÆRDI! #VÆRDI! #VÆRDI! 
miR-484 0,9177879 1,62710908 0,429114567 
miR-690 0,007146345 5,31194E-06 0,597250008 
miR-29a 2,167801204 0,608492866 0,582946796 
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